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 The goal of the current research was to examine the expression, signaling and 
function of the membrane progestin receptors (mPRs) in the ovarian follicular cells of the 
Atlantic croaker (Micropogonias undulatus) and in human breast cancer cells.  Multiple 
studies have examined the role of mPRs in the germ cells of several vertebrate classes, 
yet few studies have examined the role of the mPRs in the somatic cells of reproductive 
tissues.  Therefore this research examines the mechanism of mPR action and its function 
in somatic cells of female reproductive tissues.   
Results from studies on the expression, localization and signaling of the mPRα in 
co-cultures of granulosa and theca cells from the croaker suggest that the mPRα is 
localized to the plasma membrane of both cell types and that the mPRα is associated with 
and signals via pertussis toxin-sensitive inhibitory G proteins to decrease intracellular 
cAMP and activate ERK.  In addition, exposure of follicular co-cultures to progestins that 
activate the mPRα results in a decrease in serum starvation-induced cell death which is 
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not replicated by progestins which activate the nuclear progestin receptor (nPR), 
indicating mPR mediation.   
Similar studies in two immortalized human breast cancer cell lines, MDA-MB-
468 and SKBR3, suggest that the mPRα is also present in the membranes of these cells 
and signals in human breast cancer cell lines via activation of a pertussis toxin-sensitive 
G protein to significantly decrease in intracellular cAMP and activate ERK.  
Progesterone exposure also decreased serum starvation-induced cell death in SKBR3 
cells which are nPR positive and in MDA-MB-468 cells which are nPR negative.  
Synthetic progestins which activate the nPR but not the mPR were ineffective in 
inhibiting death in either cell type suggesting that the mPR is the mediator of this 
progestin action.   
mPRα, mPRβ and mPRγ expression analysis of paired normal and malignant 
breast tissue biopsies from thirteen women revealed that at least one mPR isoform was 
upregulated in the malignant tissue of 70% of the women.  In addition the expression of 
mPRγ was positively correlated with the expression of the nPR and CK19, a breast 
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Nuclear versus Rapid Actions of Steroids 
The mechanism of steroid hormone action has been an area of intense study for 
the last century as steroids are necessary for proper reproductive function.  The discovery 
of the nuclear estrogen receptor in the 1960’s and the subsequent discovery of a family of 
nuclear steroid receptors provided a mechanism by which steroids exerted their effects on 
target tissues (Evans, 1988).  When activated by steroids, the nuclear steroid receptor 
dimerizes and translocates from the cytosol to the nucleus of the cell where it acts as a 
transcription factor and alters gene transcription and translation.  The process of gene 
transcription and translation occurs on the order of hours to days, yet there have been 
reports of rapid steroid actions that occur on the order of seconds to minutes in the 
absence of gene translation or transcription (Revelii et al., 1998; Wehling, 1997).   
   
Mediators of Rapid Progestin Actions 
Nuclear Progestin Receptor (nPR) 
Several mammalian studies show that the nPR can initiate rapid, nongenomic 
signaling both from the cytoplasm and the cell membrane.  Studies in breast cancer cells 
demonstrate that both the ligand activated and unliganded nPR can initiate and respond to 
growth factor signaling pathways.  nPR activation of mitogen activated protein kinases 
(MAP kinases) is initiated by an interaction between a proline-rich motif on the nPR and 
SH3 domains on the upstream kinase c-Src (Boonyaratanakornkit et al., 2001).  Several 
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studies also suggest that progesterone acts via this interaction with growth factor 
signaling pathways to regulate breast cancer cell proliferation (Boonyaratanakornkit et 
al., 2007; Carnevale et al., 2007; Faivre et al., 2005; Skildum et al., 2005).  Other studies 
suggest that the nPR interacts with the nuclear estrogen receptor (ER) to indirectly 
activate MAP kinase (Migliaccio et al., 1998).  Two domains of the nPR were identified 
that interacted with the ER and were followed by ER activation of c-Src and MAP kinase 
(Ballare et al., 2003).  The interaction between nPR and ER appears to be involved in 
progestin induced proliferation of endometrial cells (Vallejo et al., 2005).  In addition to 
nPR activating rapid nongenomic signaling pathways from the cytoplasm, the nPR also 
appears to contain a highly conserved motif in the ligand binding domain which induces 
membrane localization (Pedram et al., 2007).  There are currently no reports of nPRs in 
teleost cell membranes and to date all membrane-localized progestin binding observed in 
teleosts displays the characteristics of the membrane progestin receptor.   
Membrane Progestin Receptor (mPR) 
Progestins cause final oocyte maturation in the absence of gene transcription or 
translation in several vertebrate models (Maller and Krebs, 1980; Nagahama et al., 1995) 
and induces an increase in sperm motility after only a few seconds exposure (Baldi et al., 
1998; Thomas and Doughty, 2004).  The process of steroid induced final oocyte 
maturation, the re-entry of an oocyte into meiosis and the production of a fertilizable egg, 
is being studied in several animal models including fish and amphibians.  Studies on 
oocyte maturation in teleost fishes identified a progestin binding moiety located on 
ovarian plasma membranes (Patino and Thomas, 1990).  This membrane binding-moiety 
had a high affinity (KD = 1.5 nM) for the endogenous spotted seatrout (Cynoscion 
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nebulosus) oocyte maturation inducing steroid, 17,20β,21-trihydroxy-4-pregnen-3-one 
(20β-S);(Thomas and Trant, 1989; Trant and Thomas, 1989).  The membrane-localized 
progestin receptor bound 20β-S with higher affinity than 17,20β-dihydroxy-4-pregnen-3-
one (17,20β-P) which is different from the steroid specificity profile of the cytosolic 
nuclear progestin receptor (nPR) in this species (Pinter and Thomas, 1997; Pinter and 
Thomas, 1999), indicating that the membrane and cytosolic proteins are unrelated.  
Cloning, sequencing and characterization of the membrane-localized progestin binding 
protein revealed a novel, seven transmembrane protein and confirmed that the membrane-
localized progestin binding protein was unrelated to the nuclear steroid receptor family of 
proteins (Zhu et al., 2003b).  The membrane progestin receptor (mPRα) was capable of 
binding progestins with a similar affinity (KD = 30 nM) and steroid specificity pattern to 
the membrane localized progestin binding protein in the spotted seatrout ovary when 
expressed in E. coli, confirming that the mPRα is the membrane localized progestin 
receptor in the spotted seatrout (Zhu et al., 2003b).  Multiple isoforms of the mPR 
(mPRα, mPRβ, and mPRγ) have been identified in fish as well as homologues in 
amphibians and humans (Zhu et al., 2003a).  Recent studies suggest that the mPRs are 
members of the progestin and adiponectin Q receptor (PAQR) family of proteins (Lyons 
et al., 2004; Tang et al., 2005) which are derived from a different bacterial origin than 
GPCRs (Thomas et al., 2007).  Studies on oocyte maturation in the spotted seatrout, the 
seatrout mPRα expressed by immortalized human cell lines, the human mPRα over-
expressed in immortalized human cell lines and the human mPRs in myometrial cells 
indicate that the mPRs rapidly activate a pertussis toxin sensitive G protein (Karteris et 
al., 2007; Pace and Thomas, 2005a; Thomas et al., 2007).  Additional studies on final 
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oocyte maturation in teleosts and expression of the seatrout and zebrafish mPRs in 
immortalized cell lines demonstrate the activation of p42/44 mitogen-activated protein 
kinase (MAP kinase) (Hanna et al., 2006; Zhu et al., 2003b) and suggest mPR activation 
of AKT (Pace and Thomas, 2005a; Pace and Thomas, 2005b).  Studies on progestin 
induced sperm hypermotility in the teleost model indicate the activation of the mPR by 
progestins and signaling through G proteins, yet the mechanism of mPR signaling in 
these cells differs from mPR signaling in the oocyte in that the mPR appears to associate 
with a stimulatory G protein to increase cAMP in sperm (Tubbs, 2007).  It is unknown 
whether the association of the mPR with stimulatory G proteins is isolated to male germ 
cells or if the mPR associates with multiple G proteins in females.   
Progesterone Membrane Binding Component 1 (PGRMC1) 
PGRMC1, a putative membrane progestin-binding protein, has been discovered 
by several different laboratories in several different areas of research under several 
different names.  Other names for PGRMC1 include 25-Dx (Selmin et al., 1996), Hpr6 
(Gerdes et al., 1998), VemaA (Runko et al., 1999), ratp28 (Nolte et al., 2000), and IZA 
(Raza et al., 2001).  The connection between PGRMC1 and progesterone was first 
described in sperm membranes and porcine liver microsomes (Falkenstein et al., 2001; 
Falkenstein et al., 1999; Falkenstein et al., 1998; Meyer et al., 1998; Meyer et al., 1996).  
These studies suggest that PGRMC1 is the progesterone binding protein found in porcine 
liver microsomes and that it binds progesterone with low affinity (KD = 286 nM).  Studies 
in rat granulosa cells also suggest PGRMC1 binds progesterone with low affinity (KD = 
360 nM).  In addition to binding progesterone, PGRMC1 is also suggested to bind heme, 
cholesterol metabolites and glucocorticoids (reviewed in Cahill, 2007).   A homologue of 
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PGRMC1 has also been cloned in zebrafish and is expressed in the zebrafish ovary 
(Harris, 2007).     
 
Progestin Action in the Ovarian Follicle 
Recent studies have provided much information on the actions and mechanisms of 
rapid progestin actions involving the mPR on both male and female gametes. However, 
progestins also have actions in the somatic cells of female reproductive tissues.  
Progestins increase the steroidogenic capacity of the ovarian follicle by upregulation of 
steroidogenic enzymes (reviewed in Drummond, 2006).  They also initiate ovulation in 
both teleosts (Pinter and Thomas, 1997; Pinter and Thomas, 1999) and mammals 
(reviewed in Drummond, 2006).  Several studies demonstrate progestin influence on cell 
cycle control and apoptosis of granulosa cells during the periovulatory period in birds and 
placental mammals (Chaffin and Stouffer, 2000; Engmann et al., 2006; Mussche and 
D'Herde, 2001; Peluso et al., 2006; Quirk et al., 2004; Rueda et al., 2000; Svensson et al., 
2000; Telleria et al., 1999).  Some of the apoptotic actions of progestins in the ovarian 
follicle are attributable to initiation by the nuclear receptor, yet others occur in the 
absence of nPR expression.  It is unknown if the apoptotic actions of progestins on 
ovarian follicular cells is conserved in teleosts as there is currently no information on the 
actions of progestins on teleost ovarian follicular cell cycle control or apoptosis.       
 
Progesterone and Breast Cancer 
Progestins also play important roles in normal breast development and in the 
development and progression of breast cancer in mammals.  The nuclear progesterone 
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receptors are critical for proper lobuloaveolar development though they do not appear to 
be involved in ductal morphogenesis of the breast (Shyamala, 1999; Shyamala et al., 
2000).  Progesterone has also been implicated in the development, progression and 
metastasis of breast cancer (reviewed in Lange, 2007).  Of particular interest is that 
progestin is implicated in the inhibition of breast cancer apoptosis in response to serum 
starvation and radiation in several cell lines including those which do not express the 
nuclear progesterone receptor (Moore et al., 2000; Moore et al., 2006; Vares et al., 2004).  
While the mediator of this progestin action is unknown, our previous studies using 
nuclear PR negative immortalized human breast cancer cells as models for teleost mPR 
expression and signaling found that the cells expressed human mPRs.  The role of the 
mPRs in these cells is unknown though they are potential mediators of progestin 
inhibition of cell death.  The expression of the mPRs in human breast cancer cell lines 
raises the question of whether they are involved in mPR expression in breast cancer 
development and progression and how their expression relates to other steroid hormone 
receptors.  There is currently no data concerning mPR expression in normal or malignant 
human breast tissue.      
 
Overall Goals 
The overall goals of this research were to test the hypotheses that the mechanism 
of mPR signaling and the biological function of the mPRs in the somatic cells of female 
reproductive tissues are conserved across vertebrates and that the mPRs may have 
significance in human disease.  Three specific objectives were developed to examine 
these hypotheses.  The first objective was to examine mPR expression patterns and 
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signaling in the follicular cells of a teleost fish, the Atlantic croaker Micropogonias 
undulatus, and to examine mPR-mediated progestin inhibition of serum starvation-
induced death in these cells.  The second objective was to examine mPR expression and 
signaling in two immortalized human breast cancer cell lines and to examine mPR 
mediated progesterone inhibition of serum starvation-induced death.  The final objective 
was to examine mPR expression patterns in relation to other steroid receptors in paired 
normal and malignant human breast biopsies to determine their potential role in breast 
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Progestin signaling through mPRα in Atlantic croaker granulosa/theca 




Although there is substantial evidence that membrane progestin receptors (mPRs) 
perform a critical physiological role in meiotic maturation of fish oocytes, it is not known 
whether they are also intermediaries in progestin signaling in the surrounding follicular 
cells.  Therefore, expression of mPRα, its signaling characteristics, and its physiological 
functions were investigated in co-cultured granulosa and theca cells (G/T cells) isolated 
from Atlantic croaker (Micropogonias undulatus) ovaries.  Here we show that the mPRα 
protein is expressed on the plasma membranes of both granulosa and theca cells and is 
associated with the presence of a single high affinity, limited capacity, specific progestin 
(17,20β,21-trihydroxy-4-pregnen-3-one, 20β-S)  binding site on G/T cell membranes 
with the characteristics of mPRα.  Treatment of the ovarian follicle cells with 20β-S 
caused rapid G protein activation, a transient decrease in cAMP levels and activation of 
MAP kinase, whereas the nuclear progestin receptor (nPR) agonist, R5020, was 
ineffective.  Pertussis toxin treatment blocked the 20β-S–induced decrease in cAMP 
levels and decreased 20β-S binding to the membrane receptor, both of which suggest the 
progestin receptor is coupled to an inhibitory G protein (Gi), consistent with its identity as 
mPRα.  In addition, co-immunoprecipitation experiments confirmed that mPRα is 
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coupled to an inhibitory G protein in croaker G/T cells.  A potential physiological role of 
mPRα in mediating the anti-apoptotic actions of progestins was examined in cultured 
croaker G/T cells.  The results showed that 20β-S and other progestins which activate 
mPRα decrease cell death due to serum starvation, whereas R5020, which does not 
activate mPRα, was inactive.  This is the first study to demonstrate progestin inhibition of 
G/T cell death in teleosts.  The finding that this anti-apoptotic action is mediated by 
specific mPRα agonists suggests it is mediated through this receptor and may indicate a 
novel function for mPRα in vertebrate ovarian follicular cells.   
 
Introduction 
Rapid, nongenomic actions of progestins have been known for several decades 
and have been shown to have an important role in initiating the process of final oocyte 
maturation in fish and amphibians.  Until recently the identity of the receptor mediating 
these rapid nongenomic actions of progestins on oocytes was unknown.  A membrane 
progestin receptor that is the likely intermediary in progestin induction of  oocyte 
maturation in fish was first biochemically characterized in the ovaries of spotted seatrout, 
Cynoscion nebulosus (Patiño and Thomas, 1990).  The receptor protein has high affinity 
and limited capacity specific binding for the endogenous progestin 17α,20β,21-
trihydroxy-4-pregnen-3-one (20β-S) (KD = 1.5 nM, Bmax = 7.7 nmol/gram ovary) (Patiño 
and Thomas, 1990; Thomas and Das, 1997) with ligand binding kinetics and a steroid 
specificity profile that are very different from those of the nuclear progestin receptor 
characterized in the same species (Patiño and Thomas, 1990; Pinter and Thomas, 1995; 
Pinter and Thomas, 1997), suggesting it is a novel receptor protein however, until 
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recently, the identity of this receptor was unknown.  A novel cDNA, unrelated to nuclear 
steroid receptors or any other hormone receptors, was discovered in a spotted seatrout 
ovarian library that has the characteristics of the membrane progestin receptor mediating 
progestin induction of oocyte maturation in the species (Zhu et al., 2003b). The cDNA 
encodes a ~ 40 kDa protein, named membrane progestin receptor alpha (mPRα), that has 
seven transmembrane domains and specifically binds 20β-S with high affinity in both 
recombinant E. coli expression systems (KD = 30 nM) (Zhu et al., 2003b) and in 
mammalian expression systems (KD = 7.58 nM) (Thomas et al., 2007).  Additional 
studies on mPRα suggested that it is capable of activating pertussis toxin-sensitive 
inhibitory G proteins in mammalian expression systems (Thomas et al., 2007).  Multiple 
isoforms of the mPR have been cloned in several vertebrate species including humans 
(Zhu et al., 2003a), and recent phylogenetic analyses suggest that they are members of 
the progestin and adiponectin Q receptor (PAQR) family of proteins (Lyons et al., 2004; 
Tang et al., 2005).  mPR protein expression on the oocyte cell membrane  has been 
demonstrated in several models including spotted seatrout (Pace and Thomas, 2005a; Zhu 
et al., 2003b) zebrafish (mPRα (Hanna et al., 2006)), the goldfish (mPRα (Tokumoto et 
al., 2006)) and Xenopus (mPRβ (Josefsberg Ben-Yehoshua et al., 2007) as well mRNA 
expression in the ovary of the catfish (Kazeto et al., 2005), sheep (Ashley et al., 2006) 
and human (Zhu et al., 2003a).  Of particular interest are reports of mPRα mRNA 
expression in the corpus luteum of rat (Cai and Stocco, 2005) and sheep (Ashley et al., 
2006) suggesting that mPRα  is expressed by ovarian endocrine cells as well as on the 
oocyte.  There is currently no evidence that mPRs are expressed in follicle cells.  
However, recent reports of rapid, non-genomic actions of progestins in granulosa/luteal 
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cells from a variety of species (Chaffin and Stouffer, 2000; Engmann et al., 2006; Peluso 
et al., 2006; Telleria et al., 1999) suggest membrane progestin receptors are present in 
these cells.   
 Progesterone treatment has been shown to increase granulosa cell survival in 
.oviparous birds (quail (Mussche and D'Herde, 2001)) as well placental mammals (cow 
(Quirk et al., 2004; Rueda et al., 2000), rat (Peluso et al., 2006; Svensson et al., 2000; 
Telleria et al., 1999), primate (Chaffin and Stouffer, 2000) and human (Engmann et al., 
2006)).  The mechanism of progesterone’s anti-apoptotic action remains unclear because, 
although it  has been attributed to the presence of nPR in some cell models (Mussche and 
D'Herde, 2001; Quirk et al., 2004; Rueda et al., 2000; Svensson et al., 2000), it has also 
been demonstrated in cells that lack nPR activity (Chaffin and Stouffer, 2000; Engmann 
et al., 2006; Peluso et al., 2006; Telleria et al., 1999).  Another potential mediator of 
progesterone’s anti-apoptotic actions, mPR, has not been investigated to date. The 
sciaenid fish Micropogonias undulatus, the Atlantic croaker, is a well characterized 
teleost model used to study the hypothalamic- pituitary- gonadal reproductive axis, 
ovarian steroidogenesis and oocyte maturation.   The croaker oocyte is surrounded by 
monolayers of granulosa and theca cells which can be co-cultured making it an excellent 
model for examining the actions of progestins on teleost follicular cells independent of 
the oocyte (Benninghoff and Thomas, 2006).  
 A major objective of this study was to examine whether mPRα is expressed in 
granulosa and theca cells of the Atlantic croaker and to determine the signal transduction 
pathways activated by progestins through the receptor.  Another objective was to 
determine the role of progestins in serum starvation-induced granulosa cell death in this 
 
 21
teleost fish model in order to examine the conservation of this progestin action across 
vertebrates. A final goal was to obtain preliminary information on the likely identity of 
the progestin receptor that mediates these actions.     
 
Materials and Methods 
Chemicals 
 Chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise 
noted.  20β-S, 17,20β-dihydroxy-4-pregnen-3-one (17,20β-P), estradiol-17β, testosterone 
and cortisol were purchased from Steraloids (Newport, RI).  R5020 was purchased from 
PerkinElmer (Waltham, MA).  Organon 02-0 and Organon 13-0 were obtained from 
Organon (Roseland, NJ).  Radiolabled 20β-S and 17,20β-P precursors were purchased 
from American Radiolabeled Chemicals (St. Louis, MO) and PerkinElmer NEN 
(Waltham, MA) respectively.  [1,2, 3H] 11-deoxycortisol and [1,2,6,7 3H] 17α 
hydroxyprogesterone were converted into [1,2, 3H] 17α,20β,21-trihydroxy-4-pregnen-3-
one and [1,2,6,7 3H] 17α,20β dihydroxy-4-pregnen-3-one respectively, with 20β-
hydroxysteroid dehydrogenase(20β-HSD) as described previously (Scott et al., 1982). 
Animal care and cell culture 
 Adult Atlantic croaker were purchased from local bait shops near Port Aransas, 
Texas, prior to the reproductive season and maintained in 11,000L re-circulating filtered 
seawater tanks at 24oC with 13L:11D photoperiod at the University of Texas Marine 
Science Institute.  Fish were fed a diet of commercial pellets and shrimp daily.  
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Croaker were humanely sacrificed according to NIH guidelines by procedures 
approved by the University of Texas at Austin IUCAC.  Primary granulosa and theca cell 
(G/T) cultures were obtained as described previously (Benninghoff and Thomas, 2006).  
Briefly, ovaries were harvested from sacrificed fish and mechanically dispersed with 
repeated serological pipetting.  Connective tissue was digested in 0.1% collagenase with 
gentle rotation for 1.5 hours followed by repeated serological pipetting to shear follicle 
cells from the oocytes.  Most of the oocytes settled to the bottom of the culture tube and 
the supernatant containing the G/T cells was passed through a 100 μm mesh nitex screen 
to remove any remaining oocytes.  The supernatant was then layered above a 45% percoll 
pad and centrifuged at 2800 X g for 20min.  G/T cells formed a layer at the percoll 
interface.  The cells were collected and washed with Dubecco’s Modified Eagle Medium 
(DMEM) prior to culture at an initial density of 2.5x105 cells/mL in DMEM 
supplemented with 2 percent bovine calf serum. Cells were harvested the next day for 
characterization of mPRα expression and progestin signaling 
RT-PCR 
 G/T cells were harvested directly from culture in Tri-Reagent (Sigma Aldrich, St. 
Louis, MO) and RNA was isolated following the manufacturer’s protocols.  Isolated 
RNA was DNase treated to remove any DNA using a DNA free RNA kit (Zymo 
Research, Orange CA).  Reverse transcription was performed on 1μg total RNA using 
Platinum Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA) and 500 μg/mL 
oligo(dT)s.  PCR was performed on diluted (1:10) reverse transcription reaction using 
Platinum PCR SuperMix High Fidelity (Invitrogen, Carlsbad, CA) with 200 nM final 
primer concentration.  Primers were designed against croaker mPRα (GenBank 
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Accession No. EU095257, 5’GGCAGCAGAAGAAATAGGCG, 5’ 
GCTGGCGCTACTACTTTCTCA), croaker nPR (Dr. R. Patiño, personal 
communication) (5’GGCTCCTTTTCGTCTTTGATG, 
5’CCTGATTGAAGCTGGGTACAGT), zebrafish PGRMC1 (GenBank Accession No.  
BX842703, 5’CGCTGCCCAAACTCAAGA, 5’-GTTTGGGTCCGCTCTAATC) and 
croaker 18S (5’GTTAATTCCGATAACGAACGAGACTC, 
5’ACAGACCTGTTATTGCTCAATCTCGTG) following the manufacturer’s 
instructions with an annealing temperature of 55oC for 35 cycles.  Reactions were mixed 
1:6 with BlueJuice Gel Loading Buffer (Invitrogen, Carlsbad, CA) and run on a 1% 
agarose gel and photographed.   
Western Blot Analyses  
 G/T cells were plated in 150cm2 cell culture dishes and harvested by scraping the 
following day in ice cold PBS for mPR protein detection.  The cells were briefly 
sonicated (10 seconds at a setting of 2.5 using a 550 Sonic Dismembrator, Fisher 
Scientific, Hampton, NH) on ice in the presence of HALT protease inhibitor cocktail 
(Pierce, Rockford, IL).  Nuclear fractions and unlysed cells were removed by 
centrifugation at 500 X g for 7 minutes at 4oC.  The resulting supernatant was centrifuged 
at 20,000 X g for 20 minutes to isolate the plasma membrane fraction.  The resulting 
pellet was resuspended in 1X reducing loading buffer (Pierce, Rockford, IL) and boiled 
for 10 min.  15 μg membrane protein was loaded and run on a 10% SDS PAGE gel and 
the protein bands on the gel were transferred to nitrocellulose membranes (Biorad, 
Hercules, CA).  Following transfer, membranes were washed 3 times for 5 minutes with 
PBS and blocked in 5% nonfat milk and 0.1% Tween-20 in PBS for one hour at room 
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temperature.  Croaker mPRα was detected using an antibody generated against mPRα of 
the spotted seatrout (Cynoscion nebulosus).  The seatrout mPRα antibody was produced 
against the N-terminal peptide sequence YRQPDQSWRYYFLTL.  This portion of the 
mPRα protein is identical in seatrout and croaker (GenBank Accession No. AF262028 
and EU095257 respectively).  Affinity purified spotted seatrout mPRα rabbit antiserum 
was added to membranes at a final dilution of 1:5,000 in PBS with 5% nonfat milk and 
incubated overnight at 4oC.  Membranes were washed 3X 5 min with TBS-T (20 mM 
Tris base, 150 mM NaCl, 0.1% Tween 20, pH 7.6) and incubated with secondary HRP-
linked goat anti-rabbit antibody (AbCam, Cambridge, MA) at a final concentration of 
1:5000 in TBS-T with 5% nonfat milk for one hour at room temperature.  Membranes 
were again washed 3 times for 5 minutes with TBS-T and SuperSignal West Pico 
chemiluminescent substrate (Pierce, Rockford IL) was used to visualize mPRα on ECL 
hyperfilm (Amersham, Piscataway, NJ). 
MAP kinase activation assay  
 G/T cells were cultured in 6-well cell culture plates overnight and were serum 
starved for 24-48 hours prior to steroid treatment and measurement of ERK activation.  
The serum free medium was replaced with DMEM containing steroids or vehicle and 
incubated for 5, 10, 15, 30 or 60 minutes.  Upon termination of the incubation, the media 
was rapidly removed by suction and the cells were harvested directly into 1X reducing 
loading dye (Pierce, Rockford, IL).  Samples were briefly sonicated and boiled for 10 
minutes prior to running 20 μL per sample on a 10% SDS PAGE gel and subsequent 
transfer of the protein bands to PVDF membranes (Biorad, Hercules, CA).  Membranes 
were probed using antibodies directed against total p42/44 (ERK) and phosphor-p42/44 
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(phosphor-ERK) (Biomol, Plymouth Meeting, PA) following the manufacturer’s 
suggestions and visualized using SuperSignal West Pico chemiluminescent substrate on 
hyperfilm.  Image J (NIH) was used to quantify band density.   
Immunocytochemistry 
 Cultured G/T cells were grown on glass cover slides.  All the following steps 
were conducted at 4oC.  Cells were fixed in 2% paraformaldehyde followed by three x 
five minute washings with PBS.  Cells were blocked in 3% BSA in PBS for one hour and 
then incubated overnight with mPRα primary antibody at a concentration of 1:5000.  
Negative controls were incubated in the absence of primary antibody.  Cells were washed 
3 times for five minutes with PBS followed by incubation with Alexaflor-488 linked goat 
anti-rabbit secondary antibody (Molecular Probes, Eugene, OR) at a dilution of 1:5000 in 
PBS with 3% BSA for 1 hour.  Cells were washed 3 times for 10 minutes each and 
incubated with 300 nM 6-diamidino-2-phenylindole (DAPI) for 5 minutes.  Cells were 
washed in PBS twice for 10 minutes prior to mounting using ProLong Gold Antifade 
Reagent (Molecular Probes, Eugene, OR) and visualized using a Nikon Eclipse E600 
fluorescent microscope or a Nikon C1 confocal microscope.      
[35S]-GTPγS binding to G/T cell membranes 
G/T cells were isolated from croaker ovaries and used immediately for the [35 S] 
GTPγS binding assay.  Following enzyme digestion the isolated follicle cells were 
centrifuged at 500 X g for 5 minutes to pellet live cells and resuspended in 4mL ice cold 
HAED (25 mM HEPES, 10 mM NaCl, 1 mM Dithioerythritol, 1 mM EDTA, pH 7.6) 
with HALT protease inhibitor cocktail (Pierce, Rockford, IL).  Cells were sonicated for 
10 seconds at a setting of 2.5 and the resulting homogenate was centrifuged at 1000 Xx g 
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for 7 minutes.  The supernatant was then centrifuged for 20 minutes at 20,000 X g to 
pellet the plasma membranes.  The membranes were resuspended in binding buffer (100 
mM NaCl, 5 mM MgCl2, 1 mM CaCl2, 0.6 mM EDTA, 0.1% BSA, 50 mM Tris-HCl, pH 
7.6) with HALT protease inhibitor cocktail to a concentration of 0.5 mg/mL protein.  
Membranes were pre-incubated with 10 μM GDP and 0.5 nM [35S] GTPγ-S (Amersham, 
Piscataway, NJ) in the presence or absence of 500 nM unlabeled GTPγ-S at 24oC for 5 
minutes followed by incubation in the presence or absence of various concentrations of 
steroids for 20 minutes with gentle agitation.  The reaction was terminated by rapid 
filtration onto Whatmann GF/B filters presoaked in binding buffer lacking BSA and 
washed twice with 4 mL binding buffer lacking BSA.  Specific binding was determined 
by subtracting nonspecific from total binding. 
Progestin Receptor Binding Assay 
 The binding assay was conducted following procedures described previously 
(Patino and Thomas, 1990). Cells were harvested and membranes isolated as described 
above with the final membrane pellet being resuspended in HAED.  For saturation 
binding analysis, membranes were incubated with increasing concentrations (0.25-11 
nM) of [3H]20β-S at 4oC for 30 minutes.  Nonspecific binding was determined in the 
presence of 1000 fold excess unlabeled 20β-S.  The incubation was terminated by rapid 
filtration onto Whatmann GF/B filters presoaked in HAED minus dithioerythritol 
(HAEW) using a cell harvester (Brandel, Gaithersburg MD).    The [3H]20β-S bound to 
the membranes was measured in a scintillation counter (Beckmann LS6000SC) and 
saturation curves were generated using GraphPad software (San Diego, CA).  Specific 
binding was determined by subtracting the nonspecific binding from the total binding.  
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Competition studies were conducted using a similar protocol.  Membranes were 
incubated in the presence of 100 nM competitor or ethanol vehicle with 2 nM [3H]20β-S 
for 30 minutes at 4oC.  The reaction was terminated as described previously.  The 
influence of pertussis toxin (PTX) (List Biological Campbell, CA) on [3H]20β-S binding 
was determined by pre-incubating G/T cells with 1-6 μg activated PTX or heat-
inactivated PTX (Kaslow et al., 1987) per milliliter media at 18oC for 20 minutes prior to 
membrane isolation.  Membranes were incubated with 2 nM [3H]20β-S at 4oC for 30 
minutes.  Nonspecific binding was determined in the presence of 1000 fold excess 
unlabeled 20β-S.   
  Competitive binding to the nuclear PR was conducted as described previously  
(Pinter and Thomas, 1995).  Briefly, cytosolic fractions were isolated from croaker 
ovarian fragments in TEDM buffer (10 mM Tris, 1 mM EDTA, 5 mM dithiothreitol, 10 
mM sodium molybdate, pH 7.4) and incubated with 5 nM [3H]17,20B-P in the presence 
or absence of 500 nM 17,20β-P and various concentrations of competitor for 12-24 hours 
at 4oC.  Incubations were terminated by adding 500 μL ice-cold dextran-coated charcoal 
solution (0.1% dextran, 0.4% activated charcoal in TEDM) and incubating the mixture 
for 5 minutes at 4oC followed by and centrifugation at 5000 X g for 5 minutes.         
Co-Immunoprecipitation of G protein αi subunit with mPRα 
 Cultured G/T cells from 5 150cm2 culture plates were harvested in ice-cold 
HAED and lysed by brief sonication on ice.  Nuclear fractions were pelleted by 
centrifugation at 1000 X g for 7 minutes.  The supernatant was centrifuged at 20,000 X g 
for 30 minutes to pellet plasma membranes.  Plasma membranes were resuspended in 
binding buffer with 100 μM GTP and 10 μM GDP to a concentration of 2 mg/mL protein 
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and 200 μL samples incubated in the presence or absence of 20β-S for 45 minutes at 4oC.  
Membranes were pelleted with centrifugation and resuspended in 500 μL solubilization 
buffer (150 mM NaCl, 5 mM EDTA, 0.1% SDS, 1% Triton X-100, pH 7.4) and 
incubated at 4oC with rotation.  Samples were centrifuged to remove any unsolubilized 
membrane. Antibody directed against Gαi,o,t,z (Santa Cruz, Santa Cruz CA) was added at 
a dilution of 1:200 and samples were incubated with rotation for two hours before the 
addition 25 μL of AgG coated beads (Santa Cruz, Santa Cruz CA) and further incubation 
overnight.  Beads were pelleted with centrifugation and washed three times with PBS.  
Beads were resuspended in 1X reducing western loading dye (Pierce, Rockford, IL) and 
boiled for 10 minutes.  Samples were Western blotted for mPRα.       
Cyclic AMP assay 
Cells were cultured in 6-well cell culture dishes and then serum starved for 36 
hours.  Cells were washed twice with PBS and pretreated with serum free medium 
containing 10 μM IBMX dissolved in DMSO for 20-30 minutes.  The pretreatment 
medium was replaced with media containing both IBMX and 100 nM 20β-S or vehicle 
and the mixture was incubated for various periods ranging from 1 to 30 minutes.  At the 
end of the exposure period, media were quickly removed and 100 μL 0.1M HCl was 
added to each well.  After 20 minutes of incubation with 0.1 M HCl at room temperature 
the cells were scraped from the plates, collected and stored at -20oC until assayed in 
duplicate for cAMP using an EIA kit according to the manufacturer’s instructions for 
cAMP measurement with acetylation (Cayman Chemical, Ann Arbor, MI).  For PTX 
experiments cells were pre-incubated for 30 minutes with 2 μM forskolin in the presence 
or absence of 0.5 μg/mL activated PTX or heat-inactivated PTX (hiPTX) (Kaslow et al., 
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1987)(List Biological, Campbell, CA).  100 nM 20β-S or ethanol (final ethanol 
concentration did not exceed 0.1% media volume) was added after the pre-incubation 
period and the mixture was incubated for an additional 20 minutes.  At the end of the 
incubation period the media was rapidly removed and the cell extracts were processed for 
cAMP measurement as described previously. 
Serum starvation- induced cell death 
 Cell death assays protocols were adapted from those described for breast cancer 
cells  (Moore et al., 2006).  G/T cells were cultured in 25cm2 filter-top flasks in a 
humidified 24oC chamber overnight.  The cells were washed twice with PBS (136 mM 
NaCl, 2.7 mM KCl, 12.2 mM NaPO4, 1.7 mM KH2PO4, pH 7.4) to remove all traces of 
serum and triplicate flasks were cultured in serum free DMEM in the presence of ethanol 
vehicle alone (ethanol concentration did not exceed 0.1% total volume), or various 
steroids (1-100nM) dissolved in the same volume of ethanol.  The cells were incubated 
for 5-8 days without media change with additional steroid added every two days.  At the 
end of the experiment the media were removed and adherent cells were harvested in 
Hank’s saline (5.36 mM KCl, 0.4 mM KH2PO4, 4.1 mM NaHCO3, 137 mM NaCl, 0.33 
mM Na2HPO4, 5.5 mM D-Glucose pH 7.4).  The combined media and adherent cells 
were centrifuged at 1000 X g for 3 minutes to pellet the cells.  The supernatant was 
carefully poured off and the pellet was gently resuspended in 250-500 μL Hank’s saline.  
The dead cells were identified under a microscope using trypan blue exclusion (Freshney, 
1994).   100 μL 0.4% filtered Trypan Blue Stain was added and the cells were incubated 
for 5 minutes.  Cells were loaded onto a hemocytometer and viability was determined by 
Trypan Blue Stain exclusion.  A total of 500 cells from each flask were scored for 
 
 30
viability.  This experiment was performed three times.  In other experiments cells were 
stained for DNA fragmentation (Terminal deoxynucleotidyl Transferase Biotin-dUTP 
Nick End Labeling, TUNEL) using the ApoAlert DNA Fragmentation Assay Kit 
(Clontech, Mountain View CA) as per manufacturer’s instructions.  TUNEL labeled cells 
were counted for five random fields of view on a Nikon Eclipse E600 fluorescent 
microscope.  This experiment was performed three times.   
Statistical Analyses 
 One way ANOVA with either Dunnett’s multiple comparison or Bonferroni’s 
multiple comparison was used to determine statistical differences between control and 
experimental treatments using GraphPad Prism (San Diego, CA).  Square root or log 
transformations of the data were used as indicated in order to remove significant 
differences in variance.   
Results 
Progestin receptor expression and localization in G/T cell co-cultures 
 The presence of mPRα mRNA in croaker G/T cell co-cultures was demonstrated 
by reverse-transcription polymerase chain reaction (RT-PCR) which amplified a product 
of the predicted size, 609 bp (Figure 2-1A).  In addition, the presence of the croaker 
nuclear PR mRNA in these cells was confirmed by RT-PCR (product 351 bp). Moreover, 
a product of the expected size (401 bp) was amplified using primers designed against a 
conserved sequence of the putative progesterone receptor, PGMRC1, in zebrafish (Figure 
2-1A).  Reverse transcriptase negative controls showed lack of DNA contamination 
(Figure 2-1A).  Immunofluorecent analyses demonstrated that the mPRα protein is 
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expressed on the plasma membranes of the G/T cells.  Western blot analysis of G/T cell 
membranes using an antibody directed against the N terminus of the seatrout mPRα 
resulted in the detection of a single immunoreactive band at 80 kDa, likely representing 
an mPRα dimer (Figure 2-1B).  Immunocytochemistry using the same antibody shows 
specific mPRα localization on the plasma membranes of these cells (Figure 2-2A) and its 
presence on both granulosa and theca cells in the follicular culture (Figure 2-2B).  
Intracellular, perinuclear mPRα staining can also be seen in some cells and is likely 
mPRα in the endoplasmic reticulum.  Visualizing the cells under confocal microscopy 
reveals punctate staining of mPRα on the surface of the follicular cells (Figure 2-2C).  
Cells stained with only secondary antibody did not demonstrate staining (Figure 2-2D). 
 [3H]20β-S binding to G/T cell membranes 
The progestin hormone in croaker, 20β-S, bound to the plasma membranes of 
croaker G/T cell co-cultures with characteristics typical of steroid membrane receptors.  
Saturation binding analysis revealed a single, high affinity (KD = 1.7 nM 20β-S), limited 
capacity (Bmax = 0.0975 nM or 0.39 fmol/mg protein) progestin binding site on follicular 
plasma membranes (Figure 2-3A).  Single point competitive binding studies showed that 
the binding is specific for progestins. 100 nM 20β-S, progesterone, and the synthetic 
progestins Organon 02-0 and Organon 13-0, caused significant displacement of [3 H]20β-
S from the binding site, whereas 100 nM testosterone displayed low affinity for the 
receptor and estradiol-17β and cortisol were ineffective as competitors (Figure 2-3B).   In 
order to determine whether synthetic progestins may be used to distinguish between the 
actions initiated by the mPR and the nPR, competition studies were performed with 
Organon 02-0 (J.Kelder, Organon, personal communication.) which has been shown to 
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have mPRα agonist activity on progestin induction of oocyte maturation in zebrafish 
(Harris, 2007), and with the synthetic nuclear PR agonist, R5020,  which has low binding 
affinity for seatrout and human mPRαs in mammalian expression systems (Thomas et al., 
2007).  Competition for mPR binding sites on croaker ovarian membranes showed that 
Organon 02-0 (EC50 =  44 nM) bound mPR with an affinity approximately one order of 
magnitude lower than the endogenous progestin 20β-S (EC50 = 2.6 nM), whereas R5020 
(EC50 = 297 nM) bound to the mPR with an affinity two orders of magnitude lower than 
20β-S (Figure 2-3C).  Competition for nPR binding sites in croaker ovarian cytosolic 
preparations showed that the binding affinity of R5020 (EC50 = 6.3 nM) for the nuclear 
receptor was within one order of magnitude of that of the endogenous progestin 17,20β-P 
(EC50 = 0.73 nM) (Figure 2-3D), but was two orders of magnitude higher than its 
affinity for the mPR.  It is concluded from these competitive binding studies that 
Organon-02 is a candidate for a mPR agonist in Atlantic croaker and that concentrations 
of R5020 in the range of 10-100 nM should act as a selective agonist of nPR-mediated 
progestin actions. 
 Possible coupling of the membrane progestin receptor in ovarian G/T cells to 
inhibitory G proteins (Gi and Go) was investigated by examining specific binding of 
[3H]20β-S to follicle cell membranes after uncoupling the G proteins by pretreatment 
with PTX.  Pre-incubation of cells with activated PTX significantly decreased specific 
[3H]20β-S binding by 30 percent compared to control and heat-inactivated PTX 
determined by one way ANOVA and Dunnett's multiple comparison test p < 0.05, n = 3 
(Figure 2-3E), suggesting that the progestin receptor on G/T cell membranes is coupled to 
an inhibitory G protein.    
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G protein activation in response to 20β-S exposure 
In order to determine whether the membrane progestin receptor activates G 
proteins, binding of [35S]GTPγ-S to G/T cell membranes was assessed after treatment 
with progestins.  [35S]GTPγ-S binding to G/T cell membranes increased significantly 
after treatment with 20-100 nM 20β-S and 20nM Organon 02-0 above that measured in 
the vehicle (ethanol) treated controls, but was not altered in response to treatment with 20 
nM R5020 (one way ANOVA **p < 0.001, n = 7; and Dunnett's multiple comparison test 
*p < 0.05, n = 3, Figure 2-4A). These findings are further evidence that the progestin 
membrane receptor in croaker G/T cells activates G proteins upon ligand binding and are 
consistent with its identity as mPRα. 
Co-immunoprecipitation of mPRα with an inhibitory G protein  
mPRα was co-immunoprecipitated using an antibody directed against Gαi,o,t,z , 
followed by Western blot analysis using a mPRα antibody (Figure 2-4B), suggesting that  
mPRα is coupled to  an inhibitory G protein.  In addition, the amount of mPRα protein 
co-immunoprecipitated with Gi was decreased after pretreatment with higher 
concentrations of 20β-S (290 nM, Fig.2-4B, lane1), while the amounts of Gi 
immunoprecipitated after treatment with 29  nM 20β-S were similar to the no treatment 
controls (Figure 2-4B, lane 3).  This result is consistent with G protein/receptor 
dissociation upon ligand activation, and is further evidence that the mPRα activates an 
inhibitory G protein.   Pre-immune serum did not immunoprecipitate either mPRα (lane2) 
or Gi (lane 4), confirming the specificity of the antibody precipitation reactions.  
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cAMP response to 20β-S exposure 
The demonstration that 20β-S treatment of G/T cells causes decreases in whole 
cell cAMP levels in a PTX-dependent manner would further support the proposed 
mechanism of progestin action through activation of an inhibitory G protein and the 
resulting decrease in adenylyl cyclase activity. The cAMP levels in the G/T cells were 
determined after treatment with 100 nM 20β-S for various time periods ranging from 1 to 
30 minutes. Cells exposed to 20β-S showed a significant transient 5-fold decrease in 
cAMP levels at 10 minutes (one way ANOVA and Bonferroni’s multiple comparison test 
p < 0.01, n = 13) which was observed in 5 separate experiments (Figure 2-5A).  Pre-
incubation with PTX, but not heat-inactivated PTX, blocked the inhibitory effect of 20β-
S treatment on cAMP production by forskolin-treated G/T cells (one way ANOVA and 
Dunnett's multiple comparison test *p < 0.05, **p < 0.001, n = 6, Figure 2-5B).  This 
PTX-dependent decrease in cAMP levels is consistent with progestin down-regulation of 
adenylyl cyclase activity through activation of an inhibitory G protein. 
ERK activation by 20β-S exposure 
 Progestin activation of p42/44 MAP kinase (ERK) has been demonstrated in 
croaker oocytes, suggesting activation of a β/γ subunit G protein signaling pathway (Pace 
and Thomas, 2005b).  To determine whether 20β-S causes activation of ERK in G/T 
cells, the cells were treated with 100 nM 20β-S and ERK activation was measured at 
various time points from 5 to 60 minutes (Figure 2-6).  Western blotting showed that 
exposure of follicular cells to 20β-S resulted in an increase of ERK phosphorylation 
beginning at 10 minutes (Figure 2-6A).  Mean ERK activation was increased 5 fold over 
initial (time 0) levels after 10 and 15 minutes treatment with 100 nM 20β-S (one way 
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ANOVA and Dunnett’s multiple comparison on square root transformed data to remove 
variance inequality p < 0.05, n = 3) (Figure 2-6B).  These results suggest that activation 
ERK is a potential signaling pathway through which progestins could inhibit apoptosis in 
G/T cells.   
Modification of G/T cell death by progestins 
 In order to determine whether mPR activation by progestins mediates changes in 
serum starvation-induced death, cells were serum starved and treated with both natural 
and synthetic progestins.   A decrease in the incidence of follicular cell death, assessed by 
trypan blue exclusion,  was observed after 5-8 days of progestin treatment in G/T cultures 
obtained from ovaries containing a high percentage of fully grown oocytes (one way 
ANOVA and Dunnett’s multiple comparison p < 0.0001, n = 9)(Figure 2-7A).  In 
addition, treatment of the cells with R5020 at concentrations which should activate the 
nPR did not result in an alteration of cell death, indicating that this function of progestins 
in G/T cells is not mediated by the nPR.  TUNEL staining of the G/T cells indicates that 
the number of cells which have undergone DNA cleavage is reduced by 20β-S but not by 
R5020 (one way ANOVA and Dunnett’s multiple comparison p < 0.001, n = 20) (Figure 
2-7B).  These data suggest that progestin inhibition of cell death occurs via a progestin-
induced decrease in the incidence of DNA fragmentation likely mediated by mPR 





This study is the first to demonstrate mPRα localization in granulosa and theca 
cells of any vertebrate species suggesting that mPRα may mediate physiological 
functions of progestins in the ovarian follicle. The mPRα protein is expressed in the 
plasma membranes of cultured Atlantic croaker G/T cells and is associated with specific 
progestin binding characteristic of mPRα.  Experiments also demonstrate that the mPR 
signals via activation of an inhibitory G protein to decrease intracellular cAMP in a 
pertussis toxin sensitive manner and rapidly increases ERK phosphorylation in croaker 
G/T cells which is consistent with progestin/mPR signaling in other systems.  In addition, 
the current results show that progestins alter G/T apoptosis in fish ovarian follicle cells, 
suggesting this function of progestin is conserved in different vertebrate classes.  The 
finding that specific mPRα agonists, but not nPR agonists, exert these effects provides 
initial evidence for a novel function of the mPR as the mediator of progestin inhibition of 
apoptosis in fish.  
The results of the present study demonstrate the presence of a functional 
membrane progestin receptor on granulosa and theca cells in Atlantic croaker ovaries. 
The receptor on croaker G/T cells has a single high affinity binding site with a binding 
affinity for 20β-S (KD 1.5 nM) almost the same as that for the seatrout ovarian receptor 
(KD 1.7 nM) (Patiño and Thomas, 1990). Several lines of evidence are consistent with the 
identity of this receptor being mPR. The recombinant seatrout mPRα produced in a 
human breast cancer over expression system has a similar binding affinity for 20β-S with 
a KD of 7.58 nM (Thomas et al., 2007).  The saturation analysis shows that [3 H]20β-S 
rapidly associates with the G/T cell membrane progestin receptor and binding reaches 
equilibrium within 30 minutes, in agreement with the rapid binding kinetics observed 
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with recombinant seatrout mPRα (Thomas et al., 2007).  Moreover, the specificity of 
binding to G/T cell membranes is specific for progestins and is the same as the steroid 
specificity of seatrout mPRα expressed in E. coli and mammalian cells (Thomas et al., 
2007; Zhu et al., 2003b). The binding of [3 H]20β-S to croaker G/T cell membranes was 
significantly displaced by 20β-S and progesterone, and weakly displaced by testosterone 
whereas, R5020, estradiol-17β and cortisol were ineffective competitors as has been 
observed previously for recombinant seatrout mPRα (Thomas et al., 2007).  In addition, 
two synthetic progestins, Organon 02-0 and Organon 0-13, which have relatively high 
binding affinities for recombinant human mPRα (unpublished observation), and are 
agonists on mPRα-mediated induction of oocyte maturation in zebrafish (Harris, 2007), 
were also effective competitors for 20β-S binding to G/T cells.  In contrast, the steroid 
binding characteristics of the G/T cell membranes differ from those of nPR and 
PGMRC1, which were also identified by RT-PCR in croaker ovarian follicle cells. The 
nuclear receptor agonist, R5020, displays a much higher affinity for the cytosolic 
progestin receptor in G/T cells than  it does for the progestin receptor on the cell 
membranes of these cells. Recombinant mammalian PGMRC1 and the partially purified 
protein display relatively low affinity binding to progestins, with KDs in the 200 to 300 
nM range (Meyer et al., 1996; Peluso et al., 2001; Peluso et al., 2006), 30-40 times lower 
than the progestin binding affinity of the G/T membranes, and also bind cortisol with 
relatively high affinity (Cahill, 2007). Taken together, the current data strongly suggest 
that the progestin binding protein expressed on G/T cell membranes is mPRα and further 
suggests that any progestin activity initiated at the membrane surface is acting via the 
mPR.   
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In addition to G/T cell membranes displaying progestin binding characteristic of 
mPRα, rapid progestin-initiated G protein signaling in these cells is consistent with 
previously observed mPRα signaling.  Exposure of cell membranes to 20β-S and the 
selective membrane receptor agonist Organon 02-0 but not the selective nuclear receptor 
agonist R5020 results in a significant increase in G protein activation, measured by the 
incorporation of a radiolabeled, non-hydrolysable form of GTP ([35S] GTPγS) into the 
cell membrane.  This suggests first, that 20β-S and Organon 02-0 bind a receptor on the 
cell membrane which can activate G proteins and second, that the receptor is not the 
nuclear receptor.  mPR activation of G proteins has also been demonstrated by 
recombinant seatrout mPRα expressed in mammalian cells (Thomas et al., 2007), human 
mPR in myometrial cells (Karteris et al., 2006) and endogenous mPR in croaker sperm 
(Tubbs, 2007).   
Progestin/mPRα activation of a pertussis toxin-sensitive inhibitory G protein in 
croaker G/T cells is consistent with previous studies examining the intracellular signaling 
pathways activated by mPRs.   Antibodies directed against a suite of inhibitory alpha 
subunits (Gαi,o,t,z) of heterotrimeric G protein complexes co-immunoprecipitated mPRα in 
croaker G/T cells indicating that mPRα is physically associated with an inhibitory G 
protein in these cells though it does not establish  direct coupling between the two.  These 
data agree with previous findings that recombinant seatrout mPRα expressed in 
mammalian cells and human mPRα expressed in immortalized cancer and myometrial 
cells are co-immunoprecipitated with inhibitory G proteins (Karteris et al., 2006; Thomas 
et al., 2007).  Pertussis toxin inhibition of progestin membrane binding in G/T cells is 
additional evidence for a direct coupling between mPR and G proteins as PTX acts to 
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uncouple inhibitory alpha G protein subunits from their receptors.  A decrease in 
progestin binding upon pertussis toxin exposure indicates that the association between the 
mPR and the G protein is necessary for maximal progestin binding and suggests a 
conformational change in the mPR structure in the absence of a G protein.  PTX 
inhibition of progestin binding has also been demonstrated in the seatrout ovary (Pace 
and Thomas, 2005a), by recombinant seatrout mPRα and human mPR (Thomas et al., 
2007).   
The characteristics of progestin activation of second messenger signaling in 
croaker G/T cells are also consistent with the identity of the receptor mediating progestin 
actions being mPRα.  Decreases in the intracellular levels of cAMP upon progestin 
exposure, presumably via a down regulation of adenylyl cyclase, by the inhibitory alpha 
G protein have been observed in multiple studies including those in seatrout oocytes 
(Pace and Thomas, 2005a), recombinant seatrout mPR, and mPR in immortalized cancer 
and myometrial cells (Karteris et al., 2006; Thomas et al., 2007).  The sensitivity of 
progestin induced cAMP decreases to activated pertussis toxin in all of these studies 
more specifically indicates that the mPR is coupled to a Gαi subunit.  Exposure of croaker 
G/T cells to 20β-S also increases p42/44 ERK activation presumably via the actions of 
the β/γ G protein subunits and is also in agreement with previous studies.  Progestin 
induced activation of ERK via mPR activation has been demonstrated in studies on other 
teleost mPRs (Hanna et al., 2006; Zhu et al., 2003b).  Taken together, these data 
demonstrating mPR association with a PTX- sensitive G protein, PTX sensitive decreases 
in intracellular cAMP and the activation of ERK indicate conservation of mPR signaling 
in a variety of female reproductive tissues.      
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mPRα expression on the plasma membranes of both granulosa and theca cells in a 
puncatate pattern consistent with its identity as a membrane localized steroid receptor is 
final evidence that the functional membrane localized progestin receptor in croaker G/T 
cells is the mPR.  Immunocytochemical staining of the mPRα in co-cultures of granulosa 
and theca cells clearly reveals the presence of mPRα on the plasma membranes.  mPRα 
appears to be expressed in both the elongated theca cells and the rounded granulosa cells 
indicating that the mPRα is present in both follicular cell types.  Expression of mPRα in 
both follicular cell subtypes agrees with the description of biochemically isolated 
progesterone binding sites on plasma membranes from independently isolated granulosa 
and theca cells (Rae et al., 1998) and the expression of mPRα in both follicular cell types 
suggests a biological function of the mPR which involves both granulosa and theca cells 
as opposed to only one or the other.  mPRα staining was seen on the plasma membranes 
of granulosa and theca cells and also intracellularly particularly around the nucleus.  
While there is not direct evidence, the intracellular staining of mPRα is likely mPR in the 
endoplasmic reticulum.  Membrane proteins are trafficked to the plasma membrane via 
the endoplasmic reticulum and there are reports of G protein coupled receptors becoming 
“trapped” in the endoplasmic reticulum with only a small portion becoming fully active 
and trafficked to the plasma membrane (Petaja-Repo et al., 2000).  Thus, it is not 
abnormal to see mPR staining on the endoplasmic reticulum.  Immunocytochemistry also 
revealed punctate staining of the mPRα in follicular cells.  Puncate staining of membrane 
receptors is often associated with localization of proteins to clathrin coated signaling rafts 
on the plasma membranes and is consistent with mPRα functioning as a G protein 
coupled receptor.  
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There are multiple potential functions of progestins in croaker G/T cells including 
regulation of follicular cell apoptosis and steroidogenesis.   Progestin treatment has been 
shown to regulate steroidogenic enzyme expression and activity in several mammalian 
systems.  Progestins increase P450SCC and 3β-HSD message in porcine granulosa cells 
(Rodway et al., 1999a; Rodway et al., 1999b; Swan et al., 2002) and may inhibit 
P450arom activity and estradiol production in rat granulosa cells (Fortune and Vincent, 
1983; Schreiber et al., 1981).  Treatment of granulosa and theca co-cultures from Atlantic 
croaker with 20β-S resulted in an increase in testosterone production over ethanol treated 
cells yet further investigation into this action of progestins in croaker G/T cells suggested 
that this was not due to a progestin receptor mediated action but rather due to conversion 
of progestin to testosterone by these cells (data not shown).  Thus steroidogenic responses 
of croaker G/T cells to progestin were not explored further.    
  Exposure of croaker G/T cells to progestin was shown to inhibit follicular cell 
apoptosis.  This data suggests that the anti-apoptotic action of progestin on follicle cells is 
a conserved action of progestins across multiple vertebrate orders although the 
mechanism of this progestin action may differ across vertebrates.  The protective effects 
of progestin seen in other species around the periovulatory period occur in the teleost 
follicle when a high percentage of the follicles in the ovary are fully grown and ready to 
undergo final oocyte maturation and release.  Croaker are batch spawners and fully 
grown follicles may be protected from apoptosis in the presence of 20β-S just prior to 
spawning allowing for the synchronization of oocyte maturation and enabling the fish to 
spawn a large number of fertilizable eggs.  This phase of croaker ovarian development is 
similar to the periovulatory period in mammals when the majority of  progesterone’s 
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protective effects on granulosa cells have been seen (Chaffin and Stouffer, 2000; 
Engmann et al., 2006; Quirk et al., 2004; Rueda et al., 2000; Svensson et al., 2000; 
Telleria et al., 1999).  The introduction of progestin to these cells in vivo would signal the 
proximity of spawning as 20β-S levels remain extremely low, if not completely absent, 
until just prior to spawning.  Interestingly, apoptosis of the ovarian follicle has been 
shown to be critical in the re-absorption of the post-ovulatory follicle (Drummond et al., 
2000) as well as in the atresia of excess vertebrate oocytes (Johnson, 2003) and thus the 
absence or decline in progestins post spawning would result in apoptosis of the follicle 
and re-absorption of the oocytes.   
While croaker G/T cells likely express three potential progestin receptors only the 
mPR exhibits the binding and signaling characteristics necessary for mediation of 
progestin’s anti-apoptotic actions.  The presence of mRNAs encoding mPRα, PGRMC1 
and nPR suggest the expression of three potential progestin receptors in the teleost 
follicle: two novel membrane localized receptors and one nuclear receptor.  Competition 
studies on cytosolic fractions confirm the presence of a functional nuclear receptor in the 
ovary of the croaker as has been previously described in the ovaries of closely related 
spotted seatrout (Pinter and Thomas, 1995).  nPR expression in the follicular cells of the 
ovary was expected as nuclear receptor appears to be responsible for ovulation of mature 
oocytes from the teleost ovarian follicle (Pinter and Thomas, 1999). The nPR is 
expressed by both granulosa and theca cells in the human (Maybin and Duncan, 2004), 
and the dog (Vermeirsch et al., 2001) and bovine granulosa/luteal cells (Van den Broeck 
et al., 2002) as well as those of rats (Natraj and Richards, 1993), primates (Duffy et al., 
1997) and humans (Misao et al., 1998a; Misao et al., 1998b).  RT-PCR using primers 
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designed against zebrafish PGRMC1 identified a product of predicted size (~400bp) in 
G/T cell mRNA suggesting the presence of PGRMC1 in these cells.  PGRMC1, a 28kD 
single transmembrane protein was first characterized in sperm (Falkenstein et al., 1999) 
and subsequently characterized in rat spontaneously immortalized granulosa cell (SIGC) 
membranes (Peluso et al., 2001; Peluso et al., 2006).  PGRMC1 has also been found in 
cultured human granulosa/luteal cells (Engmann et al., 2006) and rainbow trout (Mourot 
et al., 2006), where it appears to be expressed in the follicle cells as well as in zebrafish 
oocytes (Harris, 2007).  While the current study does not examine interactions between 
the three potential progestin receptors the co-expression of mPRα, PGRMC1 and nPR in 
croaker G/T cells during the period of gonadal recrudescence suggests the possibility of 
cross-talk between these three receptors while progestin levels are high. While there is 
evidence of mPR crosstalk with the nPR there is no published evidence that mPRs 
interact directly with PGRMC1.  Evidence of mPR crosstalk with the nPR is seen in 
human myometrial cells where mPR mediates functional progesterone withdrawal just 
prior to birth (Karteris et al., 2006).  In myometrial cells mPR activation decreases the 
expression of nPR coactivators necessary for nPR transcriptional activity. 
The protective function of progestin in croaker granulosa and theca cells is 
initiated by the endogenous progestin at low nanomolar concentrations of 20β-S and a 
selective human mPR agonist Organon 02-0 (which binds to mPR in Atlantic croaker) 
but not by R5020 or 17,20β-P at concentrations which should activate the nuclear 
receptor but not the membrane receptor indicating that this action is not initiated by the 
nPR.  Additionally, the presence of a single progestin binding site on follicular cell 
membranes with the characteristics of the mPR and the identification of mPRα on the 
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plasma membranes of the follicle cells indicates that mPR is the only functional progestin 
receptor in these cell membranes and suggests that PGRMC1, while possibly involved, is 
not the primary progestin receptor initiating 20β-S’s protective effects against serum 
starvation-induced cell death.  The manner of cell death inhibited by progestins is 
controlled and not necrotic in nature as indicated by TUNEL staining.  The pattern of cell 
death determined by TUNEL staining is the same as the pattern determined by trypan 
blue exclusion confirming that the decrease in cell death is due to a decrease in the 
incidence of DNA cleavage, a controlled cell death process, and not an uncontrolled 
necrotic process.    A potential mechanism for mPR inhibition of apoptosis is mPR 
activation of ERK and Akt.  The current study shows progestin activation of ERK in G/T 
cells and progestin has been shown to activate ERK in the oocyte (Pace and Thomas, 
2005b) and mPR has been shown to activate ERK in human cell lines stabling expressing 
spotted seatrout mPRα (Zhu et al., 2003b) and zebrafish mPRα and mPRβ (Hanna et al., 
2006).  Progestin has also been shown to activate Akt in croaker oocytes (Pace and 
Thomas, 2005b).  Both ERK and Akt activation have been shown to both directly and 
indirectly inhibit apoptosis in mammals (Song et al., 2005).   Activated ERK up-regulates 
the expression of anti-apoptotic members (Lin et al., 2002) and inactivates the pro-
apoptotic members (She et al., 2002) of the Bcl-2 family of proteins.  Akt directly inhibits 
apoptosis through inhibition of the pro-apoptotic Bcl-2 family member BAD (Datta et al., 
1997) and caspase 9 (Cardone et al., 1998), an upstream mediator of apoptosis.  While 
mPR activation of ERK and Akt suggest a possible mechanism for mPR inhibition of 
apoptosis further studies are needed to gain a fuller understanding of the link between 





The data presented in this study are the first to demonstrate mPR expression, 
membrane localization and signaling in the ovarian follicle of any vertebrate species.  In 
addition, mPR activation of an inhibitory G protein, decreases in cAMP and activation of 
ERK appear to be conserved in female vertebrate reproductive tissues.  This study also 
demonstrates that inhibition of apoptosis in the ovarian follicle is also a conserved 
function of progestins in teleost fish.  This work is also the first to suggest a novel anti-
apoptotic role for the mPR in the ovarian follicle and to link the mPR to apoptotic 
processes.  Additional studies are needed to elucidate the signaling mechanism leading 
from progestin activation of mPR to inhibition of DNA cleavage and apoptosis and to 
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Figure 2-1: Progestin receptor expression in granulosa and theca co-cultures.  A.  nPR, 
mPRα and PGRMC1 mRNA expression using reverse transcription polymerase chain 
reaction on isolated follicular cells.  RT plus and RT minus shown to confirm lack of DNA 
contamination.  B.  Western blotting in granulosa and theca cell plasma membranes using 
an antibody directed against an N terminal seatrout mPRα peptide showed a single 















Figure 2-2: mPRα localization in granulosa and theca co-cultures.  
Immunocytochemistry of granulosa and theca cell cultures using an antibody directed
against the N terminal region of the mPRα and DAPI nuclear staining showed mPRα
expression on the plasma membrane (A) of both cell types (B) in a punctate pattern (C).  










Figure 2-3:  Characteristics of progestin binding in granulosa and theca cells. A.  
Representative saturation and Scatchard binding of radiolabled 20β-S to granulosa and 
theca co-culture plasma membranes. kD= 1.7nM 20β-S,  Bmax= 0.0975nM or 
0.39fmol/mg protein.   B.  Single point competition with 100nM competitor for 20β-S 
binding to plasma membranes of granulosa and theca cell cocultures. Data represents 
means ± SEM.  Statistically significant differences from vehicle control were determined 
using one way ANOVA and Dunnett's multiple comparison test *p<0.001, n=3.  
Progesterone (P4), Testosterone (T), Estradiol (E2), cortisol (F).  C.  Competition with 
[3H]20β-S for  plasma membrane localized mPR binding by 20β-S (EC50=2.6nM),
Organon 02-0 (EC50=44nM), and R5020 (EC50=297nM).  Competition binding curves are 
generated from the average of three experiments.  D. Competition with [3H]17,20β-P for 
cytosolic PR binding by 17,20β-P (EC50=0.73nM) and R5020 (EC50=6.3nM). Competition 
binding curves are generated from the average of three experiments. E.  Effect of 1ug/mL 
pertussis toxin (PTX) or heat inactivated PTX (hiPTX) on [3H] 20β-S binding to 
membranes. Data represents means ± SEM from a representative replicate.  Statistically 
significant differences from ethanol control were determined using one way ANOVA and 
Dunnett's multiple comparison test *p<0.05, n=3.
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Figure 2-4: G protein activation in response to 20β-S exposure. A:  Specific binding of 
[35S]GTPγS to plasma membranes of Atlantic croaker granulosa and theca cells in 
response to 20nM-100nM steroid.  Data represents means ± SEM.  Statistically significant 
differences from ethanol control were determined using one way ANOVA and Dunnett's 
multiple comparison test **p<0.001, n=7 *p<0.05, n=3 B: Semi-quantitative co-
























































































Figure 2-5:  cAMP response to 20β-S exposure in cultured Atlantic croaker granulosa and 
theca cells. Cells were serum starved for 24 hours and pre-incubated with 100uM IBMX and 
0.5ug/mL PTX or hiPTX (as indicated) for 15 minutes prior to progestin exposure.  
Cell extracts were collected at the indicated time points and assayed for cAMP by ELISA. 
(Cayman Chemical) A: Whole cell cAMP levels over 30 minutes following 100nM 20β-S 
exposure. Data represents means ± SEM.  Statistically significant differences were 
determined using one way ANOVA and Bonferroni’s multiple comparison test *p<0.01, 
n=13.  B:  Whole cell cAMP levels after 30 minutes exposure to 100nM 20-β-S with forskolin
and PTX pretreatment. Data represents means ± SEM of log transformed data to remove 
variance inequality.  Statistically significant differences from forskolin control were 
determined using one way ANOVA and Dunnett's multiple comparison test *p<0.05, 
**p<0.001, n=6.































































































































Figure 2-6: ERK activation in granulosa and theca co-cultures by 100nM 20β-S.  A.  
Representative blot showing ERK phosphorylation upon 100nM 20β-S exposure.  B.  
Band density shown as percent time 0 adjusted for total ERK protein of treated and 
control cell extracts. Data represents mean percent band density to time 0 adjusted to 
total p42/44 ± SEM.  Statistically significant differences from time 0 were determined 
using one way ANOVA and Dunnett's multiple comparison test on square root 
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Figure 2-7:  Modification of granulosa and theca cell death by progestins. A. Changes in 
the rate of granulosa and theca cell serum starvation induced death in response to 
progestins measured by trypan blue exclusion after 5-8 days exposure.  Data represents 
means ± SEM.  Statistically significant differences from ethanol control were determined 
using one way ANOVA and Dunnett's mulitple comparison test *p<0.0001, n=9.  B.  
TUNEL stained nuclei in response to 6-7 days progestin exposure. Data represents 
means ± SEM.  Statistically significant differences from ethanol control were determined 



















































































































































Membrane progesterone receptor (mPR) expression and signaling in 
breast cancer cells and potential role in progestin inhibition of apoptosis 
 
Summary  
 The expression, signaling and potential biological role of endogenous membrane 
progesterone receptors (mPRs) in SKBR3 and MDA-MB-468 breast cancer cell lines 
were evaluated.  Quantitative PCR shows the presence of transcripts for mPRα, mPRβ 
and mPRγ in both cell lines with mPRα mRNA expression 10 times higher than that of 
mPRβ or mPRγ .  Western blotting demonstrated the presence of mPRα, mPRβ and 
mPRγ proteins in plasma membrane fractions prepared from both cell lines.  Western 
blotting also detected the presence of the nPR in SKBR3 cells but not in MDA-MB-468 
cells.   Progesterone bound to SKBR3 cell membranes with similar characteristics to 
those of mPRα shown in previous studies.  The nuclear receptor agonist and antagonist, 
R5020 and RU486, did not compete for progesterone binding, indicating that the nPR is 
not the primary progesterone receptor expressed on SKBR3 cell membranes.  Exposure 
of SKBR3 cells to progesterone resulted in rapid activation of an inhibitory G protein, a 
decrease in intracellular cAMP levels and p42/44 MAP kinase activation, consistent with 
progestin signaling through mPRs.  Exposure of MDA-MB-468 cells to progesterone also 
resulted in rapid G protein activation.  Treatment of serum starved SKBR3 cells and 
MDA-MB-468 cells with progesterone and the mPR agonist Organon 02-0 resulted in 
significant, dose-dependent decreases in cell death and DNA fragmentation, whereas   
testosterone, estradiol, dexamethasone, RU486 and R5020 treatments were ineffective.  
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Inhibition of cell death and DNA fragmentation was not accompanied by inhibition of 
caspase 3 activity, which suggests progesterone inhibits an alternative, caspase-
independent death pathway.  This is the first study to demonstrate expression and 
signaling of endogenously expressed mPRs in immortalized breast cancer cell lines.  In 
addition, these results provide an initial indication that progesterone inhibition of 
apoptosis in these cells is mediated through mPRs.  Involvement of mPRs in the 
development or progression of breast tumor growth through inhibition of cell death is an 
intriguing possibility and requires further investigation.  
 
Introduction 
Breast cancer is the second most common cancer in women and accounts for up to 
one third of cancer diagnoses in American women (American Cancer Society, ACS, 
2003-2004 Breast Cancer Facts and Figures).  Nearly 70% of breast cancers are steroid 
hormone-responsive and express either the nuclear estrogen or progesterone receptors 
(ACS Hormone Therapy).  Because so many breast cancers proliferate in response to 
steroids, a wide variety of treatment options have been developed that block steroid 
action or synthesis in order to inhibit tumor growth. 
Expression of the nuclear progesterone receptor (nPR) is often viewed as a marker 
of estrogen responsive malignancies, but a growing body of evidence indicates that 
progesterone receptor expression as merely an indication of estrogen-responsive growth 
may be an over simplification (Fuqua et al., 2005; Moore, 2004).  Clinical evidence of 
progesterone’s, in addition to estrogen’s, effect on tumor development and growth was 
demonstrated in the Women’s Health Initiative (WHI) Randomized Trial (Chlebowski et 
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al., 2003) which was terminated early due to an increased risk of breast cancer 
development exceeding the predefined stopping boundary.   In addition, laboratory 
investigations have shown that progesterone causes proliferation of  several  
immortalized breast cancer cell lines which express high levels of progesterone receptor 
and little or no estrogen receptor (Horwitz et al., 1978).  Based on findings that 
progesterone has effects on breast cancer cell lines independent of estrogen, investigators 
have concluded that further studies are needed on the role of progesterone and 
progesterone receptors in breast cancer (Fuqua et al., 2005; Moore, 2004). 
Nuclear steroid receptors are ligand-activated transcription factors that modulate 
the expression of a wide range of genes, including those regulating cell proliferation 
(Basu and Rowan, 2005; Ikeda and Inoue, 2004).  Proliferation of cells mediated via 
nuclear steroid receptors through genomic mechanisms is a slow process requiring new 
mRNA and protein synthesis.  However, rapid, non-nuclear signaling of progestins 
ultimately resulting in cell proliferation in immortalized breast cancer cell lines has also 
been reported.  Studies examining progestin actions in breast cancer have shown that 
progestins are able to rapidly activate growth factor signaling pathways via direct, non-
nuclear-mediated action through the nPR (Boonyaratanakornkit et al., 2001; Faivre et al., 
2005; Lange et al., 1998; Lange et al., 1999; Skildum et al., 2005) and via cross- talk 
between the nPR and nuclear estrogen receptors (nER) (Ballare et al., 2003; Migliaccio et 
al., 1998; Vallejo et al., 2005) resulting in breast cancer cell growth and development of 
metastasis (Carnevale et al., 2007).  Progestins also inhibit apoptosis of human breast 
cancer cells.  While there is evidence that the nPR mediates progestin inhibition of 
apoptosis in several systems it is less clear in others, especially in breast cancer cell lines 
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which do not express the nPR.  Medroxyprogesterone acetate, an nPR agonist, is able to 
inhibit serum starvation-induced apoptosis only in breast cancer cell lines which express 
the nPR (Ory et al., 2001) and the nPR antagonist RU486 is able to inhibit progestin 
protection from radiation induced apoptosis in T47D breast cancer cells (Vares et al., 
2004).  While these studies suggest nPR mediation of progestin’s anti-apoptotic actions 
in these cells other studies examining progestin inhibition of apoptosis have found 
progestin response in an nPR negative cell line (Moore et al., 2006).  In addition, the 
activation of Akt by progesterone appears to be necessary for progesterone’s anti-
apoptotic actions in MCF-7 cells but no direct link between Akt activation and the nPR 
was established (Alkhalaf et al., 2002).  One possible mediator of progesterone actions, 
particularly in nPR negative cells, is the membrane progesterone receptor (mPR).  The 
mPR was first identified, cloned and characterized in the ovaries of the Cynoscion 
nebulosus (Zhu et al., 2003b) and three isoforms (mPRα, mPRβ, and mPRγ) were 
subsequently cloned in humans (Zhu et al., 2003a).  The human mPRs are seven- 
transmembrane proteins expressed on the plasma membrane of cells which bind 
progestins in a specific, displaceable, high affinity, limited capacity manner, 
characteristic of steroid membrane receptors (Thomas et al., 2007; Zhu et al., 2003a).  In 
addition, mPRs activate G proteins in several cell types (Karteris et al., 2006; Thomas et 
al., 2007), although it is not a classical G protein coupled receptor (GPCR) but a member 
of the progestin and adipoQ receptor (PAQR) family (Lyons et al., 2004; Tang et al., 
2005).  The mPR expression has been shown in several breast cancer cell lines 
irrespective of nuclear steroid receptor expression.  mPRs are expressed by MCF7 cells 
which express both the nPR and the nER as well as in SKBR3 cells which do not express 
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the nER but do express low levels of the nPR and in MDA-MB-231 cells which do not 
express either nER or nPR  (Dressing and Thomas, 2007).  Given that mPR is expressed 
in both nPR positive and negative cells, it is reasonable to suggest that mPR may mediate 
progestin’s anti-apoptotic effects in the absence of the nPR and that mPR may be 
involved in progesterone’s actions in the presence of nPR.   
The objectives of this study were to examine the expression, signaling and 
biological function of mPRs in human breast cancer cell lines in order to asses their 




 All chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless 
otherwise noted.  Progesterone, estradiol, testosterone and cortisol were purchased from 
Steraloids (Newport, RI).  RU486 was purchased from Sigma Aldrich and R5020 and 
[1,2,6,7,3H (N)] progesterone were purchased from PerkinElmer (Waltham, MA).  
Antibodies for mPRα, mPRβ and mPRγ were generated by SigmaGenosis for Peter 
Thomas.  mPRα polyclonal antibodies were generated against the peptide sequence 
TVDRAEVPPLFWKPC, mPRβ polyclonal antibodies were generated against the peptide 
sequence KILEDGLPKMPCTVC and mPRγ polyclonal antibodies were generated 
against the peptide sequence TDIKNDSYSWPMLC in rabbits.  Antibodies directed 
against the nPR (Progesterone receptor Ab-8) were purchased from Lab Vision 
ThermoFisher (Fremont, CA).  Integrin β-3 antibodies were purchased from Cell 
Signaling and β-actin (clone C-4) antibodies from MP Biomedical (Solon, OH).  HRP-
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linked secondary antibodies against rabbit and mouse were purchased from AbCam 
(Cambridge, MA) and Cell Signaling (Danvers, MA) respectively.   p44/42 MAP kinase 
and Phospho-p44/42 MAP kinase antibodies were purchased from Cell Signaling 
(Danvers, MA).   
Cell Culture 
SKBR3 and MDA-MB-468 cells were obtained from American Type Culture 
Collection (Manassas, VA).  SKBR3 cells were cultured in phenol red-free Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 14 mM NaCO3, 
penicillin/streptomycin/glutamine solution, gentamicin and 10% certified fetal bovine 
serum (FBS)(Gibco, Carlsbad, CA).  MDA-MB-468 cells were cultured in Lebowitz-15 
medium supplemented with 14 mM NaCO3, penicillin/streptomycin/glutamine solution, 
gentamicin and 10% certified FBS.  Media were changed every second day.  Cultures 
were maintained in a humidified chamber at 37oC with 5% CO2 and sub-cultured using 
0.05% trypsin with EDTA (Gibco, Carlsbad, CA) as necessary.   
Real Time PCR 
 Cells were washed with PBS (136 mM NaCl, 2.7 mM KCl, 12.2 mM NaPO4, 1.7 
mM KH2PO4, pH 7.4) and harvested from 25 cm2 flasks directly in TRI reagent (Sigma, 
St. Louis MO) and RNA was isolated as per manufacturer’s instructions.  Samples were 
DNase treated to remove any DNA using a DNA free RNA kit (Zymo Research, Orange 
CA).  PCR was performed using Brilliant II SYBR Green QRT-PCR Mastermix 1-Step 
(Stratagene, Cedar Creek TX) for mPRα, mPRβ, mPRγ, (See Table 3-1 for primer 
sequences) on a Mastercycler ep realplex2 (Eppendorf, Westbury, NY).    
Preparation of Membranes 
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Cells were grown to 70-90% confluence in 150 cm2 culture plates, washed with 
PBS and serum starved overnight.  The cells were collected in 4 mL ice cold HAED (25 
mM HEPES, 10 mM NaCl, 1 mM dithioerythritol, 1 mM EDTA, pH 7.6) with HALT 
protease inhibitor cocktail (Pierce, Rockford IL).  Cells were sonicated for 10 seconds at 
a setting of 2.5 and centrifuged at 1000 X g for 7 minutes at 4oC to remove unlysed cells 
and nuclear material.  The supernatant was then centrifuged at 20,000 X g at 4oC for 20 
minutes to pellet the membrane fraction.  The supernatant was carefully removed under 
suction and the pellet was resuspended with buffer for subsequent experimentation.  
Western Blot Analysis for mPRs and nPR 
Plasma membranes for mPRα, mPRβ, mPRγ and integrin western blotting  were isolated 
as described above from SKBR3 and MDA-MB-468 cells, resuspended in PBS with 
HALT protease inhibitor cocktail and added in the ratio of 2:1 to 5X Lane Marker 
Reducing Sample Buffer (Pierce, Rockford IL) and loaded on a 10 % SDS-PAGE gel (15 
μg protein/lane measured by the Bradford method).  MagicMark Protein Ladder or 
BenchMark Pre-stained Protein Ladder (Invitrogen, Carlsbad CA) were run on each gel 
for protein size determination.  SKBR3, MDA-MB-468 and MCF-7 cells were harvested 
for nPR and actin western blotting.  Cells were harvested in PBS and centrifuged at 500 
X g for 5 minutes to pellet the cells.  Pellets were resuspended in 1 mL PBS containing 
protease inhibitor cocktail and lysed by sonication.  Crude cytosolic extracts were 
obtained by centrifugation for 20 minutes at 20,000 X g to remove nuclear and membrane 
fractions.  50 μg of SKBR3 and MDA-MB-468 cell and 20 μg (to avoid nPR 
overloading) MCF-7 cell cytosolic extracts were loaded into sample wells.  All samples 
were boiled for 10 minutes and cooled on ice prior to being run onto an 8% (for nPR) or 
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10% (for mPRs) SDS PAGE gel. The protein bands separated by electrophoresis were 
transferred onto nitrocellulose membranes.  The membranes were blocked in PBS with 
0.1% Tween-20 and 5% non-fat dry milk for 1 hour at room temperature.  Membranes 
were washed in PBS three times for 5 minutes and incubated with primary antibody 
(dilution mPR antibodies-1:2500; dilution nPR antibody 1:10) in 5% non-fat dry milk 
overnight at 4oC.  After incubation with primary antibodies, membranes were washed 
three times for five minutes with TBS-T (20 mM Tris base, 150 mM NaCl, 0.1% Tween 
20, pH 7.6) and incubated with an appropriate HRP-linked secondary antibody (1:2500) 
following the manufacturer’s dilution recommendations at room temperature for one 
hour.  Membranes were washed three times for five minutes with TBS-T.  Supersignal 
WestPico was added (Pierce Rockford IL) to the membranes and membranes were 
exposed to Hyperfilm ECL (Amersham Piscataway NJ).  Film was developed using 
Kodak developer and fixer (VWR, West Chester, PA).    
  MAP kinase activation assay 
Cells were passed into 6-well cell culture plates (VWR, West Chester, PA) at 
2x105 cells per milliliter (three mL per well) and allowed to grow to 70% confluence.  
Cells were washed twice with PBS and fresh serum-free media were added.  After 36 
hours of serum starvation the cells were again washed twice with PBS and cultured with 
serum free media for 30 minutes prior to adding progesterone  (final concentration:  100 
nM in ethanol) or an equal volume (< 0.1% of total media volume) of ethanol carrier.   
The cells were incubated with progesterone for 5, 10, 15, 30 or 60 minutes and the 
incubation was terminated by rapidly removing the media by suction and followed by 
washing the cells with ice-cold PBS.  Cells were scraped into 100 μL 1X Lane Marker 
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Reducing Sample Buffer (Pierce, Rockford IL).  Samples were prepared for western 
blotting by sonication at a setting of 2.5 for 5 seconds and boiled for 10 minutes prior to 
loading 20 μL sample/well onto a 10% SDS PAGE gel.  Following separation, proteins 
were transferred onto nitrocellulose membranes.  The membranes were blocked in TBS-T 
and 5% non-fat dry milk for 1 hour at room temperature.  Primary antibody was added 
(1:1000) and membranes were incubated overnight at 4oC with gentle agitation. After the 
primary antibody incubation, membranes were washed, incubated with an HRP-linked 
goat anti-rabbit secondary antibody (1:2500), and visualized as described above.  
Radiolabled GTPγS binding and immunoprecipatation 
Cells were grown to confluence in 150 cm2 culture dishes.  Cells were washed 
twice with PBS and serum starved for 12 hours prior to membrane preparation.  For the 
binding assay, the membranes were isolated following the protocol described previously 
and resuspended in binding buffer (100 mM NaCl, 5 mM MgCl2, 1 mM CaCl2, 0.6 mM 
EDTA, 0.1% BSA, 50 mM Tris-HCl, pH 7.6) with protease inhibitor cocktail (Sigma, St. 
Louis MO) to a concentration of 0.5 mg/mL.  250 μL membrane re-suspension was added 
to an equal volume of 1 nM [35S] GTPγ-S and pre-incubated with 10 μM GDP in the 
presence or absence of 500 nM unlabeled GTPγ-S (BioMol, Plymouth Meeting, PA) at 
room temperature for 5 minutes.  Steroids or ethanol of various concentrations were 
added at the end of the pre-incubation period and the mixture was incubated with gentle 
agitation for a further 15 minutes at room temperature.  The binding experiment was 
terminated by rapid filtration of triplicate 100 μL reaction volumes onto Whatmann GF/B 
filters presoaked in BSA-free binding buffer and washed twice with 4 mL of the same 
buffer.  For the immunoprecipitation experiment the membranes were resuspended in 
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binding buffer with protease inhibitor cocktail to a concentration of 2 mg/mL.  500 μL of 
the membrane suspension was added to an equal volume of 8 nM [35S] GTPγ-S and pre-
incubated with 10 μM GDP and in the presence or absence of 500 nM unlabeled GTPγ-S 
(BioMol, Plymouth Meeting, PA) at room temperature for 5 minutes.  Steroids or ethanol 
of various concentrations were added to 200 μL aliquots of the reaction mixtures at the 
end of the pre-incubation period and the samples were incubated with gentle agitation for 
a further 30 minutes at 4oC.   Binding was terminated with the addition of 750 μL ice-
cold 100 μM GDP/GTPγ-S in binding buffer to the 200 μL reaction volume.  All the 
following procedures were completed at 4oC.   Membranes were pelleted using 
centrifugation at 20,000 X g for 30 minutes and resuspended in 200 μL solubilization 
buffer (1% Triton X-100, 0.1% SDS, 150 mM NaCl, 5 mM EDTA, 25 mM Tris-HCl, pH 
7.4) with fresh protease inhibiting cocktail and incubated with gentle rotation for 2 hours.  
Antibodies directed against various G proteins were added at a concentration of 1:200 
(Santa Cruz, Santa Cruz CA) and samples were incubated over-night with rotation.  The 
following day samples were again centrifuged at 20,000 X g for 30 minutes and 
supernatants were added to 25 μL Protein A/G beads and incubated with gentle rotation 
for an additional 2 hours.  Beads were washed three times with wash buffer (50 mM 
HEPES, 100 µM NaF, 50 mM sodium phosphate, 100 mM NaCl, 1% Triton X-100, 0.1% 
SDS, pH 7.4) and boiled in 100 μL PBS with 0.5% SDS for 10 minutes.  Radioactivity 
was counted on a scintillation counter (Beckmann LS6000SC) for both the binding and 
the immunoprecipitation experiments.      
   cAMP measurement 
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Cells were grown to approximately 70% confluence in 6-well culture plates.  
Prior to experimentation the cells were washed twice with PBS and then serum starved 
for 36 hours.  Cells were washed with PBS and pretreated with serum-free media 
containing 10 μM IBMX dissolved in DMSO for 20-30 minutes.  Progesterone at a final 
concentration of 100 nM or ethanol vehicle (< 0.1% media volume) were added and 
incubated for 0, 1, 5, 10, 15 or 30 minutes.  At the end of the incubation period, the media 
was quickly removed and 100 μL 0.1M HCl was added to each well.  After 20 minutes 
treatment with HCl the cells were scraped off the plates, collected and stored at -20 °C 
until assayed by ELISA in duplicate according to the manufacturer’s instructions 
(Cayman Chemical, Ann Arbor, MI). 
Cell Death Assay 
Cell death assays protocols were adapted from previous studies (Moore et al., 
2000; Moore et al., 2006).  Briefly, cells were grown in 25 cm2 flasks.  Upon 100% 
confluence the cells were washed twice with PBS and fresh, serum free media with 
various steroid concentrations was added to duplicate or triplicate flasks.  The cells were 
incubated from four to seven days with no medium changes.  Steroid was supplemented 
every second day with the addition of 1μL ethanol containing steroid per 3.5 mL media.  
Upon conclusion of the experiment, the incubation media was removed and placed into a 
15mL tube.  The adherent cells were harvested by washing them twice with 2 ml Hank’s 
saline solution, followed by incubating them for 5 minutes in 2 mL Hank’s saline.  
Hank’s saline solution from the washes and Hank’s saline solution containing adherent 
cells was added to the media from the incubation and centrifuged at 1000 X g for 5 
minutes to pellet all cells.  Cells were resuspended in 250 μL Hank’s saline.  50 μL 0.4% 
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filtered Trypan Blue Stain was added and the cells were incubated for 5 minutes.  Cells 
were loaded onto a hemocytometer and viability was determined by Trypan Blue Stain 
exclusion.  A total of 500 cells from each flask were scored for viability.  All experiments 
were repeated at least three times. Some data was square root transformed to remove 
differences in variance as indicated. 
TUNEL assay 
Cells were grown in 25 cm2 flasks.  Upon reaching 100% confluence the cells 
were washed twice with PBS and fresh serum free media with various steroid 
concentrations were added as described above.  The cells were incubated for 24-48 hours 
and harvested in Hank’s saline solution as described above.  TUNEL was performed 
according to the manufacturer’s instructions (Clontech, Mountain View, CA) using the 
ApoAlert DNA Fragmentation Assay.  Apoptotic nuclei were counted using a Nikon 
Eclipse E600 fluorescent microscope as a proportion of total cells in 5 random fields of 
view for each flask.     
Caspase 3 Activity 
Cells were treated as in the TUNEL assay.  Cells were harvested and caspase 3 
activity was determined using Caspase-3 ApoAlert Assay plate (Clontech, Mountain 
View CA) as per manufacturer’s instructions.   
Statistical Analyses 
One way ANOVA with either Dunnett’s multiple comparison or Bonferroni’s 
multiple comparison was used to determine statistical differences between control and 
experimental treatments using GraphPad Prism (San Diego, CA).  Square root 
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transformations of the data were used as indicated in order to remove significant 
differences in variance.    
 
Results 
Identification of mPR and progesterone binding 
 QPCR shows the presence of mRNAs of all three mPR isoforms in both SKBR3 
and MDA-MB-468 cell lines (Figure 3-1A).  mPRα mRNA levels were 10 times higher 
then mPRβ or mPRγ in both cell lines.  SKBR3 cells appear to express higher levels of 
mPRα and mPRγ than MDA-MB-468 cells while the MDA-MB-468 cells contain 
slightly higher levels of mPRβ mRNA.    
 Western blotting for the mPRs shows the presence of 80 kD mPRα and mPRβ 
dimers and a 40 kD mPRγ monomer in both SKBR3 and MDA-MB-468 cell membranes 
(Figure 3-1B).  SKBR3 cells appear to express slightly more mPRα and mPRγ proteins 
than MDA-MB-468 cells while MDA-MB-468 cells have higher mPRβ expression which 
is consistent with the QPCR results.  The nPR is weakly expressed by SKBR3 cells while 
no nPR was found in MDA-MB-468 cells (Figure 3-1C). 
 Saturation and Scatchard analyses of [3H]-progesterone binding demonstrate the 
presence of a high affinity (KD = 10.59 nM progesterone), limited capacity (Bmax = 0.33 
nmol/mg protein), single progesterone binding site on SKBR3 membranes (Figure 3-1D).  
A single point competitive binding assay showed that 50 nM progesterone was very 
effective in displacing [3 H]-progesterone binding to the receptor (Figure 3-1E). Two 
synthetic progestins, Organon 02-0 and Organon 13-0,  which have high binding 
affinities for the progestin receptor on croaker G/T cell membranes, were also relatively 
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effective competitors at a concentration of 50 nM for [3 H]-progesterone binding to the 
receptor on SKBR3 cell membranes. Testosterone (50 nM) caused slight displacement of 
[3 H]-progesterone binding, whereas the nuclear progesterone receptor agonist and 
antagonist R5020 and RU486, and cortisol and estrogen were ineffective as competitors 
of [3H] progesterone binding to SKBR3 membranes (Figure 3-1E).   
mPR G protein signaling 
Progesterone treatment (20 nM) caused significant increases in [35S] GTPγS 
binding to both SKBR3 (Figure 3-2A) and MDA-MB-468 (Figure 3-2B) cell membranes. 
At a concentration of 100 nM, progesterone caused a 30% increase in [35S] GTPγS 
binding to SKBR3 cell membranes over control values (one way ANOVA and Dunnett’s 
multiple comparison *p < 0.05, **p < 0.001, n = 4 and Student’s t-test *p < 0.05, n = 3 
respectively).  Immunoprecipitation experiments using solubolized SKBR3 membranes 
showed a significant (one way ANOVA Dunnett’s p < 0.05, n = 5) 150% increase in the 
amount of [35S] GTPγ-S immunoprecipitated by antibodies directed against inhibitory G 
proteins upon progesterone exposure and no significant increase in of [35S] GTPγ-S 
immunoprecipitated by antibodies directed against stimulatory G proteins (Figure 3-2C) 
indicating selective progesterone activation of an inhibitory G protein.   
mPR intracellular signaling  
 Exposure of SKBR3 cells to 100nM progesterone resulted in a significant (one 
way ANOVA Dunnett’s multiple comparison p < 0.05, n = 5) reduction in intracellular 
cAMP levels compared to the control no treatment values at 5, 10 and 30 minutes (Figure 
3-3A).  Progesterone also caused a transient, significant (one way ANOVA and Dunnett’s 
multiple comparison p < 0.05, n = 4) increase in p42/44 MAPK activation in SKBR3 
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cells between 5 and 30 minutes exposure which had disappeared by 60 minutes exposure 
(Figure 3-3B,C).    
Progestin inhibition of serum starvation-induced death 
 Exposure of SKBR3 cells to 10nM progesterone resulted in a significant (one way 
ANOVA and Dunnett’s multiple comparison on square root transformed data p < 0.05, n 
= 6) ~15% decrease in serum starvation-induced death assessed by trypan blue exclusion 
(Figure 3-4A) which was not replicated by the nPR agonist R5020, the nPR antagonist 
RU486, dexamethasone or estradiol-17β.  Progesterone also significantly (one way 
ANOVA and Dunnett’s multiple comparison p < 0.01, n = 6) inhibited serum starvation-
induced cell death ~14% in MDA-MB-468 cells, whereas R5020, RU486, 
dexamethasone and estradiol-17β were ineffective (Figure 3-4B). Moreover, the 
progesterone-induced decrease in cell death in SKBR3 cells appeared to be 
concentration-dependent (Figure 3-5A) with a significant decrease (~15%) in cell death 
occurring at 10 nM (one way ANOVA and Dunnett’s multiple comparison p < 0.05, n = 
9), increasing to ~35% at 1000 nM progesterone (p < 0.001). In contrast, no 
concentration –dependent effects of progesterone on cell death in MDA-MB-468 cells 
were observed over the concentration range tested in this study (Figure 3-5B). Cell death 
was inhibited ~ 20% at a concentration of 1nM, the lowest progesterone concentration 
investigated (one way ANOVA and Dunnett’s multiple comparison p < 0.001) (Figure 3-
5B). 
Progestin inhibition of DNA fragmentation 
 Treatment of MDA-MB-468 cells with progesterone and the selective mPR 
agonist Organon 02-0 resulted in a 40-55% decrease in DNA condensation detected by 
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TUNEL staining (Figure 3-6A).  Significant decreases (Dunnett’s multiple comparison 
*p < 0.05, **p < 0.001, n = 15) in DNA condensation compared to the ethanol controls 
were detected in the 1 and 10nM progesterone treatment groups (40 and 45% decrease, 
respectively) and in 10 and 100 nM Organon 02-0 treatment groups (55 and 45% 
decrease, respectively) but not with 10 nM R5020 treatment, indicating a non-nuclear 
receptor mechanism (Figure 3-6B).  These results suggest that manner of cell death 
inhibited by progestin treatment appears to be a controlled apoptotic mechanism as 
opposed to an uncontrolled necrotic process.   
Progestin effect on caspase 3 activity 
 While the mechanism of progestin inhibition of cell death appears to be regulated 
and apoptotic in nature, decreases in DNA fragmentation by progestins are not mediated 
by caspase 3 inhibition.  Treatment of serum starved MDA-MB-468 cells with 1 nM-100 
nM progesterone or 10nM R5020 was ineffective in altering caspase 3 activity in 5 
separate experiments (one way ANOVA and Dunnett’s multiple comparison p > 0.05, n = 
11) (Figure 3-7).    
 
Discussion 
 This study demonstrates expression and signaling of mPRs and their likely 
involvement in the inhibition of apoptosis in two breast cancer cell lines.  We have shown 
that SKBR3 and MDA-MB-468 cells express three isoforms of the mPR and that the 
membrane progesterone binding in SKBR3 cells and progestin signaling in both cell lines 
display characteristics previously reported for mPRα.  Progesterone-induced G protein 
signaling in both cell lines and progesterone decreased intracellular cAMP levels and 
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activated p42/44 MAP kinase in SKBR3 cells.  In addition, exposure of serum-starved 
SKBR3 and MDA-MB-468 cells to low physiological (low nanomolar) concentrations of 
progesterone but not R5020, RU486, dexamethasone or estradiol-17β resulted in 
inhibition of cell death and DNA condensation.   
mPRα, mPRβ and mPRγ mRNA and protein were found in both SKBR3 and 
MDA-MB-468 cells with quantitative PCR and western blot analyses yielding results 
similar to those found in other studies.  mPRα is the predominant mPR transcript found in 
both cell lines and agrees with similar findings from a previous study in which the mPRα 
was the primary mPR transcript detected in SKBR3, MCF-7 and MDA-MB-468 breast 
cancer cell lines (Dressing and Thomas, 2007).  Quantitative PCR analysis also 
demonstrated that SKBR3 cells expressed higher levels of mPRα transcript than MDA-
MB-468 cells and is corroborated by western blotting for mPRα in the two cell lines.  
While western blotting showed a 40 kD monomer and an 80 kD dimer in both cell lines a 
slightly stronger mPRα dimer was seen at 80 kD in SKBR3 cells.  Similarly, both 
quantitative PCR and western blot analyses results suggest that MDA-MB-468 cells 
express slightly more mPRβ than SKBR3 cells.   Western blotting for mPRβ detected 
only a dimer of 80 kD though the mPRβ monomer has been shown previously in SKBR3 
cells and in MCF7 cells (Dressing and Thomas, 2007).   The detection of 40 kD and 80 
kD mPRα and mPRβ bands have been ablated by primary antibody preincubation with 
peptide demonstrating specific antibody detection of mPRα and mPRβ monomers and 
dimers (Karteris et al., 2006; Thomas et al., 2007).  SKBR3 cells express higher numbers 
of mPRγ transcript than MDA-MB-468 cells yet both cell lines express similar amounts 
of the 40 kD mPRγ monomer.  This is the first study to examine the expression of the 
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mPRγ protein in breast cancer cells and these results may indicate that the relative 
amounts of mPRγ mRNA and protein do not directly correlate with each other.  There is 
little published data on mPRγ expression and signaling and further studies are needed to 
accurately describe mPRγ expression patterns in mammalian tissues.   
Western blotting also detected low levels of nPR protein in SKBR3 but not MDA-
MB-468 cells.  It is interesting that nPR expression is not necessary for mPR expression 
and corroborates findings that suggest that the mPRs are expressed and regulated in 
tissues independent of nPR (Karteris et al., 2006).  While studies suggest that the nPR can 
localize to the cell membranes of cultured cells (Pedram et al., 2007), the progestin 
binding to SKBR3 membranes has a binding affinity for progesterone (KD = 10.6 nM) 
within the range reported previously for recombinant mPRs (Thomas et al., 2007; Zhu et 
al., 2003a).  Stronger evidence that the progestin receptor in SKBR3 cells membranes are 
mPRs was obtained from the steroid specificity studies.  Both the membrane 
progesterone receptor in SKBR3 cells and recombinant human mPRα display high steroid 
specificity for progesterone with low affinity for testosterone and no affinity for estradiol-
17β, cortisol, the nPR agonist R5020 or the nPR antagonist RU486 (Zhu et al., 2003a)  
(Thomas et al., 2007).  Two synthetic agonists for human mPRα, Organon 02-0 and 
Organon 13-0, bind SKBR3 membranes with significant affinity, although with less 
affinity than progesterone.  Taken together, these data indicate that the progesterone 
binding displayed by SKBR3 membranes is mediated by mPRα.   
 G protein activation by progesterone exposure was seen in both SKBR3 cells and 
MDA-MB-468 cells and is of similar magnitude to mPR activation of G proteins in other 
cells and tissues.  The 20 to 30 percent increase in [35S] GTPγ-S binding to SKBR3 
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membranes with 20 and 100 nM progesterone exposure is similar to the increases in [35S] 
GTPγ-S binding to cell membranes which over-express mPRα (Thomas et al., 2007) and 
in human myometrial cells (Karteris et al., 2006) as well as similar to those seen in the 
teleost oocyte (Pace and Thomas, 2005b), sperm (Tubbs, 2007) and mammalian cells 
over-expressing seatrout mPRα (Thomas et al., 2007).  Immunoprecipitation of the 
progesterone/ [35S] GTPγ-S binding complex demonstrated a three fold activation of an 
inhibitory G protein by progesterone in SKBR3 cells which is in agreement with other 
studies on mPR-mediated G protein activation in female tissues.  Both the identity of the 
G protein activated by progesterone and the level of activation is similar to that seen in 
human mPRα over-expressed in mammalian breast cancer cells (Thomas et al., 2007), 
myometrial cells (Karteris et al., 2006) and by seatrout mPRα in teleost oocytes and 
mammalian over-expression systems (Pace and Thomas, 2005b; Thomas et al., 2007).  
Progesterone consistently activates inhibitory G proteins, presumably via mPR activation, 
in the reproductive tissues of females, yet recent studies indicate that the mPRα is 
coupled to and signals via a stimulatory olfactory G protein in teleost sperm (Tubbs, 
2007).  It is unknown at this time whether mPR activation of inhibitory subunits is seen 
only in female tissues or whether mPR association with stimulatory G proteins is isolated 
to male gametes.  
 Progesterone also causes the activation of second messenger systems consistent 
with mPRα activation in SKBR3 cells.  Exposure of SKBR3 cells to nanomolar 
concentrations of progesterone results in a twenty-five percent decrease in intracellular 
cAMP after 5 minutes.   Similar decreases in intracellular cAMP upon progestin exposure 
are also seen in human mPRα over-expression systems (Thomas et al., 2007) as well as in 
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mammalian cells expressing teleost mPRα (Hanna et al., 2006; Thomas et al., 2007; Zhu 
et al., 2003b) and in the teleost oocyte (Pace and Thomas, 2005b).  In addition to 
decreases in intracellular cAMP, SKBR3 cells exposed to progesterone also show a 
transient increase in p42/44 MAP kinase activation between 5 and 15 minutes exposure.  
Again, rapid activation of MAP kinases have been observed in mammalian cells over-
expressing the and human myometrial cells (Karteris et al., 2006) as well as in 
mammalian cells expressing teleost mPRα (Hanna et al., 2006; Zhu et al., 2003b) and 
teleost oocytes (Pace and Thomas, 2005a).  Both the progesterone binding characteristics 
and the rapid intracellular signaling patterns initiated by progesterone in SKBR3 cells are 
consistent with mPRα activation and signaling.  
 Treatment of SKBR3 and MDA-MB-468 with progestin inhibited serum 
starvation-induced apoptosis in a manner consistent with mPR mediation regardless of 
nPR expression.  Progestins which activate the mPRs were able to inhibit serum 
starvation-induced apoptosis in a dose-dependent manner in both SKBR3 and MDA-MB-
468 cells while R5020, RU486, dexamethasone and estradiol-17β did not.  Progesterone 
inhibition of apoptosis in these two cell lines is similar in magnitude to studies on other 
breast cancer cell lines (Moore et al., 2006) as well as progesterone inhibition of 
apoptosis in the ovarian follicle (Engmann et al., 2006; Mussche and D'Herde, 2001; 
Peluso et al., 2006).  Ovarian steroids have consistently been shown to regulate the 
proliferation and differentiation of normal mammary tissue (Feng et al., 1995; Medina, 
2005; Shyamala, 1999), yet their roles in the development and progression of breast 
cancer are often confusing.  Several reports indicate that progestins promote apoptosis in 
multiple breast cancer lines (Formby and Wiley, 1998; Formby and Wiley, 1999; 
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Kandouz et al., 1999; Kandouz et al., 1996) while others demonstrate progestin inhibition 
of breast cancer cell apoptosis (Bardon et al., 1987; Moore et al., 2000; Moore et al., 
2006; Ory et al., 2001; Vares et al., 2004).  Of particular interest is that some reports of 
progestin inhibition of apoptosis occur in nPR negative cell lines (Moore et al., 2006).    
Activation of p42/44 MAP kinase has been shown to inhibit apoptosis in several studies 
(Henson and Gobson, 2006; Song et al., 2005) and is a plausible mechanism for 
progesterone’s anti-apoptotic effects in SKBR3 and MDA-MB-468 cells.   Several 
studies have demonstrated progestin activation of growth factor signaling pathways.  The 
nPR contains an SH3 domain which allows it to activate Src and down stream 
extracellular signaling-regulated kinases (ERK) (Boonyaratanakornkit et al., 2001).  
Other studies demonstrate a complex interplay between the nPR and ERK where the 
progesterone receptor rapidly activates ERK (Lange et al., 1998) and then is itself 
phosphorylated by ERK which alters its transcriptional activity (Daniel et al., 2007), nPR 
subcellular localization (Qiu et al., 2003) and degradation (Lange et al., 2000).   A third 
set of studies suggest that the nPR interacts with the β isoform of the nuclear estrogen 
receptor (nERβ) (Ballare et al., 2003; Migliaccio et al., 1998) which then activates ERK 
and Akt through SH2 domains (Migliaccio et al., 2000).  Studies examining the 
interaction of the nPR with growth factor signaling pathways use pico- to nanomolar 
concentrations of the nPR agonist R5020.  Of particular note is the failure of R5020 to 
inhibit cell death in either cell line used in the current study.  R5020 is a commonly used 
nPR agonist and activates the nuclear receptor but does not bind with any affinity to the 
mPRs (Thomas et al., 2007; Zhu et al., 2003a).  The failure of R5020 to protect against 
death, even in an nPR positive cell line, indicates that progesterone may be acting 
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through a progesterone receptor other than the nPR in these cells to exert its protective 
effects.   The activation of ERK, one of which is p42/44 MAP kinase, inhibits apoptosis 
via several mechanisms and phosphorylation of p42/44 MAP kinase by the mPRs has 
been demonstrated in multiple tissues and species.  Activated MAP kinases have been 
shown to up-regulate the expression of anti-apoptotic members (Lin et al., 2002) and to 
inactivate the pro-apoptotic members (She et al., 2002) of the Bcl-2 family of proteins.  
In addition to phosphorylated ERK exerting anti-apoptotic signaling, activated Akt has 
also been shown to inhibit apoptosis both directly and indirectly.  Direct effects of Akt 
include inhibition of BAD (Datta et al., 1997), a proapoptotic member of the Bcl-2 
family, and Caspase 9 (Cardone et al., 1998), a mediator of apoptosis.  Akt activation is 
commonly associated with the activation of βγ G protein subunits and progestins have 
been shown to activate Akt in the teleost oocyte which expresses mPRα (Pace and 
Thomas, 2005a). Thus, it is likely that Akt may also be activated in SKBR3 and MDA-
MB-468 cells. 
 Caspase 3 activity is often regulated in association with DNA fragmentation 
(Porter and Jänicke, 1999) yet progesterone was not found to alter caspase 3 activity in 
this study.  There have been recent reports of cell death or apoptosis of cancer cells in the 
absence of caspase activity.  Serum free culture of REGb tumor cells results in cell death 
characterized by detached cells and DNA fragmentation in the absence of active caspase 
3 or caspase 9 (Larmonier et al., 2002).  A similar phenomenon is seen in cultured 
cortical neurons which display DNA condensation and fragmentation upon serum free 
culture in the absence of caspase activity (Hamabe et al., 2000).  Of particular interest is 
that vitamin D has been shown to induce apoptotic morphology in breast cancer cells via 
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a mechanism that does not involve caspase activity but was blocked by the 
overexpression of the anti-apoptotic Bcl-2 protein (Mathiasen et al., 1999).   Bcl-2 is also 
one of the proteins shown to be upregulated by activated ERK and Akt and may play a 
significant role in progesterone inhibition of apoptosis in SKBR3 and MDA-MB-468 
cells.  Apoptosis-like death in the absence of caspase activity has recently been 
recognized as an important mechanism of death in cultured cells (Blagosklonny, 2000).  
Some studies suggest that calpain, a calcium activated protease, and members of the Bcl-
2 family of proteins may be involved in caspase-independent apoptosis (Abraham and 
Shaham, 2004; Borner and Monney, 1999; Mathiasen et al., 2002) and may be mediating 
death in serum-starved SKBR3 and MDA-MB-468 cells.  Calpain, a calcium-regulated 
protease, is a candidate for potential mPR regulation as it has been suggested by studies 
in sheep that membrane progestin actions initiate calcium release, perhaps via mPR 
activation (Ashley et al., 2006).  The Bcl-2 family of proteins also deserve further study 
in relation to mPR activation as various members of this family are regulated by ERK 
and Akt.   
Conclusion 
 We have demonstrated endogenous mPR expression, progestin membrane binding 
characteristic of mPRα and rapid, progesterone-induced inhibitory G protein signaling in 
nPR-positive SKBR3 and nPR-negative MDA-MB-468 breast cancer cell lines.  In 
addition, progesterone protected both cell lines from serum starvation-induced apoptosis 
characterized by DNA fragmentation in the absence of changes in caspase 3 activity.  
R5020 was not able to mirror progesterone’s anti-apoptotic activity in either cell line 
suggesting that progesterone is likely mediating this action through mPR activation.  
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Further evidence that progesterone acts through the mPR to prevent apoptosis is 
suggested by progesterone’s ability to activate ERK via mPR in the present study and Akt 
in previous studies.  Other studies have shown that both activated ERK and Akt inhibit 
apoptosis through regulation of calpain and Bck-2 family proteins.  Further study is 
needed to determine the mechanism of progesterone’s protective effects, although the 
expression, signaling and the potential anti-apoptotic actions of the mPR in these 
immortalized breast cancer cell lines suggests a potential role for the mPRs in breast 
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Figure 3-1: Progesterone receptor expression in and progesterone binding to cancer cell 
membranes.  A.  Quantitiative RT-PCR on RNA isolated from SKBR3 and MDA-MB-468 
cells using primers directed against mPRα, mPRβ and mPRγ.  B.  Western blotting for 
mPRα, mPRβ and mPRγ on SKBR3 and MDA-MB-468 cell membranes.   C.  Western 
blotting for nPR in SKBR3 and MDA-MB-468 cell lysates.  MCF-7 lysate used as positive 
control.  D.  [3H] progesterone saturation binding on SKBR3 plasma membranes. Kd
10.59nM   Bmax: 0.33nmol/mg protein.   E.  Single point competition of 50nM steroid for 





















































































































































































Figure 3-2: G protein activation in response to progesterone.  A.  Specific binding of 
[35S] GTPγS to SK-BR-3 membrane fractions in response to increasing concentrations of
progesterone.  Data represent mean ± SEM. Statistically significant differences from 
ethanol control were determined using one-way paired ANOVA, and Dunnett’s Multiple 
Comparison  *p<0.05, **p<0.001,  n=4.  B. Specific binding of [35S] GTPγS to MDA-MB-
468 cell membranes.  Data represent means ± SEM.  Significant differences from ethanol 
were determined using Student’s t-test *p<0.05, n=3. C. Immunoprecipitation of [35S] 
GTPγS in response to 20-100nM progesterone by G protein antibodies in SK-Br-3 cell 
membranes.  Data represent mean percent ethanol specific [35]GTPγS binding.  
Differences from control determined by one way *ANOVA  and Dunnett’smulitple
comparison p<0.05, n=5.
































































































































Figure 3-3: Intracellular signaling in response to progesterone exposure.   A.  cAMP 
concentration time course in whole SK-BR-3 cells in response to 100nM progesterone.  
*Data represents mean percent time 0 cAMP normalized to protein ± SEM.  Statistical
difference from time 0 determined by paired one way ANOVA  and Dunnett’s multiple 
comparison p<0.05, n=5.  B.C. MAP kinase activation by 100nM progesterone in SK-BR-3 
cells. Representative blot (B) and densitometry (C) from four separate experiments 
shown.  Data represent mean phospho-p42/44 band density normalized to total p42/44 
band density ± SEM.  Statistically significant differences from time 0 were determined 
using paired  one way ANOVA and Dunnett’s multiple comparison *p<0.05, n=4.  





































































































Figure 3-4:  Alteration of serum starvation-induced cell death by 10nM steroid.   A..  
SK-BR-3 cell death determined by trypan blue exclusion after 5-7 days of serum 
starvation.  Data represent mean ± SEM.  Difference between ethanol and steroid 
treatment determined by one way ANOVA  and Dunnett’s multiple comparison on square 
root  transformed data *p<0.05, n=6.  B.  MDA-MB-468 cells.  Data represent mean ±
SEM.  Significant difference between ethanol and steroid treatment determined by one 
































































































































Figure 3-5: Cell death in response to progestins.  A. SKBR3 cell death determined by 
trypan blue exclusion in response to progesterone after 5 days of serum starvation.  Data 
represent mean death ± SEM.  Significant difference from control determined by one way 
paired ANOVA  and Dunnett’s multiple comparison *p<0.05  **p<0.001, n=9.  B.  MDA-
MB-468 cell death after 4 days exposure to progesterone. Data represent mean death ± 
SEM.  Significant difference from ethanol determined by one way paired ANOVA  and 






















































































































































Figure 3-6: DNA fragmentation in MDA-MB-468 cells in response to progestins.  A .  
TUNEL staining B.  TUNEL staining in response to 48 hours exposure to progestins.  
Data represent mean  percent TUNEL stained nuclei ± SEM.  Differences between 
vehicle and treatment determined by  one way ANOVA  and Dunnett’s multiple 















































































































Figure 3-7: Progesterone effect on caspase 3 activity.   Effect of 10nM 
progesterone on caspase 3 activity in MDA-MB-468 cells.  Data represent mean 
activity normalized to protein and control treatments.  Difference from control 










































Membrane progesterone receptor α, β and γ expression in paired 
normal and malignant human breast biopsies and their expression 
patterns in relation to other steroid receptors 
 
Summary 
 The expression and signaling of nuclear steroid hormone receptors in human 
breast cancer is a topic of intense research and has been used as a diagnostic tool in breast 
cancer treatment for nearly 40 years.  Several laboratory and clinical studies in the last 20 
years have suggested that progesterone plays a significant role in breast cancer 
development, progression and metastasis independent of its modulation of estrogen 
effects.  While there is information concerning progesterone’s activity in breast cancer 
via the nuclear progesterone receptor (nPR), there are reports of progesterone actions in 
breast cancer cells which do not express the nPR.  Recently three isoforms of a recently-
discovered novel membrane localized progesterone receptor (mPRα, mPRβ and mPRγ) 
were identified in several human breast cancer cell lines and therefore are candidates as 
the receptors involved in progesterone’s anti-apoptotic effects in breast cancer.  
Quantitative reverse-transcription PCR was used in the current study to examine the 
expression patterns of the three mPR isoforms in paired normal and malignant breast 
biopsies from 13 women.  While expression of the mPRs was lower than that of the 
nuclear steroid receptors in all of the biopsy samples examined, one or more of the mPR 
isoforms was upregulated in 85% and mPRγ was upregulated in 70% of the tumors 
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examined.  Further analysis indicated that mPRα upregulation appeared to be associated 
with nuclear progesterone receptor upregulation and mPRγ upregulation was linearly 
correlated to the breast epithelial cell marker CK19.  This study is the first to examine 
mPR expression levels in normal and malignant human breast biopsies.  The patterns of 
mPR expression observed in malignant breast tissue in the present study suggest a 
potential role for the mPRs in breast cancer biology.           
 
Introduction 
 Steroid receptor-positive tumors constitute up to seventy percent of the diagnosed 
breast cancer cases in the United States (American Cancer Society).  Steroid receptor 
status influences patient treatment and may serve as an indicator of survival.  
Investigations of steroid receptor influence on breast cancer development, progression 
and treatment has primarily focused on nuclear estrogen receptor (ER) function.  Most 
treatment options directed against steroid responsive cancers inhibit estrogen promotion 
of cell growth and division by using selective estrogen receptor modulators (SERMs) to 
block or impair the ability of estrogen to activate the ER and/or aromatase inhibitors 
which inhibit endogenous estrogen production.  SERMs used to treat ER-positive breast 
tumors include the popular drugs tamoxifen and raloxifene and aromatase inhibitors 
include arimidex, letrozole and exemestane.   
The presence of the nuclear progesterone receptor (nPR) in breast tumors has 
often been viewed as an indicator of a functional estrogen receptor (Olivotto et al., 2004; 
Osborne et al., 1980) as nPR expression can be regulated by estrogen (Nardulli et al., 
1988).  Yet several studies now suggest that this may be an oversimplification of 
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progesterone and nPR  action in breast cancer (Fuqua et al., 2005; Moore, 2004).  Indeed 
multiple lines of research now suggest that progesterone may have a role in breast cancer 
development and progression independent of estrogen.  Multiple immortalized human 
breast cancer cell lines express the nPR in the absence of the ER (Horwitz et al., 1978) 
and there are clinical reports of nPR-positive ER-negative tumors (Dunnwald et al., 2007; 
Keshgegian, 1994; Keshgegian and Cnaan, 1996).  Studies in ER-negative nPR-positive 
cell lines show that progestin influences growth and cell cycle progression via a 
mechanism involving the ability of the nPR to activate cytoplasmic signaling pathways 
(Boonyaratanakornkit et al., 2001; Carnevale et al., 2007; Faivre et al., 2005; Lange et al., 
1999; Lange et al., 1998; Richer et al., 1998; Skildum et al., 2005).  Progestins have also 
been shown to promote cell survival and inhibit apoptosis in nPR-negative cell lines 
(Moore et al., 2006), suggesting novel progesterone receptors may have important roles 
in breast cancer biology.    
Clinical evidence for a direct influence of  progestins, in addition to the well 
known effects of   estrogens, on breast cancer development and growth has been 
demonstrated in several clinical trials, most notably the controversial early conclusion of 
the Women’s Health Initiative estrogen plus progestin hormone therapy due to an 
increase in the incidence in breast tumor development (Chlebowski et al., 2003; Li et al., 
2000; Persson et al., 1999; Ross et al., 2000; Schairer et al., 2000).  Thus, there is 
growing awareness of the importance of progesterone and progesterone receptors in 
breast cancer biology and as a result progesterone’s effects on breast cancer cell lines and 
in breast tumors are becoming more widely studied.   
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Progesterone inhibition of serum starvation- induced apoptosis on two 
immortalized breast cancer cell lines, one which expressed the nPR and one which did 
not, was examined earlier in this dissertation (Chapter 3).  The mediator of this 
progesterone action is likely the novel membrane progesterone receptor (mPR) which 
suggests an important role for the mPRs in breast cancer biology.  The mPR is a novel 
gene, unrelated to the nPR, first identified in the ovary of a teleost fish and three isoforms 
(mPRα, mPRβ and mPRγ) were subsequently cloned in humans (Zhu et al., 2003a; Zhu et 
al., 2003b).  The mPRs are expressed in all immortalized breast cancer cell lines 
examined to date although the ratio of each isoform differs between cell lines 
(unpublished observation).   
The goal of the current study is to examine the expression patterns of mPRs in 
relation to other ovarian steroid receptors and malignancy.  The current study examines 
the expression of the three human mPR isoforms, the nPR, two ERs, the putative 
progestin receptor PGRMC1and CK19, a breast epithelial cell marker, in paired normal 




 Paired normal and malignant biopsy samples were obtained from the NCI Human 
Tissue Network.  Samples were handled in accordance with NIH guidelines approved by 
The University of Texas office of Research Support and Compliance.  Samples were 




 RNA was isolated from 2-3 mg tissue samples in Tri Reagent (Sigma St. Louis 
MO) as per the manufacturer’s instructions.  Following RNA isolation, samples were 
DNase treated using the DNA free RNA kit from Zymo Research (Orange CA).  DNA 
contamination was tested in the absence of reverse transcriptase using primers directed 
against β-actin.  Samples with DNA contamination were DNase treated a second time.   
QRT-PCR 
QRT-PCR was performed on approximately 250 μg DNA-free RNA using 
Brilliant II SYBR Green QRT-PCR Mastermix 1-Step (Stratagene, Cedar Creek TX) on 
an Eppendorff RealPlex ep2 (Hamburg, Germany) for mPRα, mPRβ, mPRγ, nPR, ERα, 
ERβ, PGRMC1, CK19 and β-actin (See Table 4-1 for primer sequences).  Primers were 
used at final concentrations of 100 nM.  The cycling protocol used following a 30 minute 
50oC reverse transcription incubation time and a 10 minute 95oC denaturation incubation 
was as follows:  30 seconds at 95oC, 60 seconds at 55oC and 30 seconds at 72oC for 40 
cycles.   ERα and ERβ primers were purchased from RealTimePrimers.  CK19 primers 
were developed by Stathopoulou et al (2003), PGRMC1 by Crudden et al (2005) and 
NPR by Latil et al (2001).  No template control samples were performed for each sample 
to confirm the specificity of the reaction (data not shown).   
Determination of Relative Receptor Expression 
 CT values were calculated using Eppendorf software (Hamburg, Germany) and 
receptor concentrations were normalized to β-actin expression taking into account primer 





mPR expression levels  relative to other receptors 
 mPRα mRNA was 2-3 times more abundant in both normal and malignant tissues 
than either mPRβ or mPRγ suggesting that mPRα is the primary mPR expressed in breast 
tissue.  Yet overall, the expression levels of the mPRs are 2-5 times lower than other 
ovarian steroid receptors measured (Figure 4-1).   
mPR expression relative to malignancy 
Expression of mPRα, mPRβ and mPRγ mRNAs were detected in all 26 breast 
tissue biopsies examined.  Average mPRα, mPRβ and mPRγ mRNA levels are slightly 
upregulated in malignant breast tissue over normal tissue from the same breast (Figure 4-
1).  Ratios of malignant to normal gene expression ranged from 0.01 to over 100.  In 
order to simplify the data here we define upregulation as greater than 1.2:1 ratio of 
expression in malignant tissue to normal tissue which corresponds to a 20% increase in 
gene transcription (Table 4-3).  Of the thirteen women examined, mPRα was upregulated 
in 6 cases (46%), mPRβ was upregulated in 5 (38%) and mPRγ in 9 (70%, Table 4-3). 
Overall mPRγ was upregulated in a higher percentage of patients with malignant breast 
tissue (70%), than any of the other receptors (nPR: 54%; ERα: 46%; ERβ: 38%; 
PGMRC1: 38%)  
mPR upregulation in malignant tissue relative to other genes 
 Upon examination of the profile of gene upregulation in each individual, several 
patterns emerged with regard to receptor co-regulation (Table 4-3).  Only three cases 
(biopsy nos. 4, 7, 13) showed no upregulation of any mPR isoform. None of the other 
receptors were upregulated either in these three cases, indicating an overall absence of 
steroid receptor regulation in these biopsy samples. Of the remaining ten biopsy samples, 
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nine showed upregulation of mPRγ. Three cases had only one mPR isoform upregulated 
in malignant tissue and two mPR isoforms were upregulated in 4 cases (biopsy nos. 2, 3, 
6, 12).  Of particular interest is that in three cases all three mPR isoforms are upregulated 
(biopsy nos.1, 5, 8).  In all 6 cases where mPRα and most cases where mPRβ are 
upregulated mPRγ was also upregulated.  All six of the women who displayed 
upregulated mPRα expression in malignant tissue also displayed upregulation of the nPR.  
Similarly, seven out of the nine biopsies showing upregulation of mPRγ also displayed 
upregulation of nPR. Although four out of five biopsies with upregulation of mPRβ 
expression also displayed upregulation of nPR, three other biopsies with increased nPR 
expression showed no increase in mPRβ. The pattern of upregulation of the other putative 
progesterone receptor, PGMRC1, differed from those of the other receptors.  Half of the 
biopsies showing upregulation of the mPRs (5/10) and five out of seven biopsies 
displaying upregulation of nPR did not have parallel increases in PGMRC1 expression.  
The parallel regulation of mPRα, mPRγ and nPR in breast cancer tissues suggests the 
possibility of an interaction between progesterone receptors, perhaps with important 
implications in breast cancer biology.  There was a linear relationship between CK19 and 
mPRγ upregulation.  Linear regression determined a positive relationship between nPR 
and mPRγ with a slope of 14.42 ± 3.846.  p < 0.005 indicated a slope significantly 
different from 0 with r2 = 0.5609 (Figure 4-2A).   Linear regression was used to 
determine a positive relationship between CK19 and mPRγ with a slope of 0.1430 ± 
0.02262.  p < 0.0001 indicated a slope significantly different from 0 with r2 = 0.7842 
(Figure 4-2B).  The expression pattern of ERβ upregulation differed from those of the 
other receptors, including ERα, and was only observed in two of the thirteen cases. In 
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contrast, upregulation of ERα corresponded to upregulation of mPRα in four out of six 
cases (67%) and nPR the same number of times (67%). There was no correlation between 
mPR expression and tumor origin, race or Bloom/Richardson Grade.  Alternatively age 
does appear to influence mPR expression patterns.  The average age of women who show 
no mPR upregulation or only mPRγ upregulation was 41 years old while the average age 
of women who showed upregulation of two or more mPR isoforms was 59, suggesting 
that mPR upregulation may occur in breast cancer of postmenopausal women more 
frequently than in younger women.       
 
Discussion 
The current study is the first to describe the expression patterns of mPR isoforms 
in human breast cancer biopsies.  While the transcript levels of mPRs are somewhat 
lower compared to nuclear steroid receptors, mPRγ appears to be upregulated in 70 
percent of the tumors examined which is similar to the proportion of tumors defined as 
steroid receptor positive (Varghese, 2007).  The ratio of mPRγ upregulation in malignant 
breast tissue is also positively correlated with CK19 upregulation, a marker of epithelial 
cells.  We also discovered that mPRα, the most abundant of the mPR isoforms, and 
mPRγ, the most ubiquitous of the mPR isoforms, appear to be co-regulated with nPR 
which suggests the possibility of an interaction between the two progesterone receptors.  
This study shows that the mPRs are widely expressed in breast tumors with at 
least one mPR isoform upregulated in 85% of the tumors examined.  Steroid receptor 
expression in breast cancer has been used for 30 years to determine tumor responsiveness 
to endocrine therapy (Allegra et al., 1980; De Sombre et al., 1974; Horwitz and McGuire, 
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1975; Knight et al., 1980) and future prognosis.  Several studies suggest that patients with 
steroid responsive tumors have lower mortality rates than ER-/PR- cancers (Aaltomaa et 
al., 1991; Anderson et al., 2001; Crowe et al., 1991; Dunnwald et al., 2007; Fisher et al., 
1988; Parl et al., 1984; von Maillot et al., 1982) (Furmaniski et al., 1980; Howat et al., 
1985).   This is likely due to the finding that the degree of tumor differentiation and 
histology grade is the single most important histological risk factor for survival in breast 
cancer (Parl and Dupont, 1982) and steroid responsive tumors, in general, show a higher 
degree of differentiation (Reiner et al., 1988).   
  Breast tumor steroid responsiveness has historically focused on estrogen but 
several studies have begun to examine the effects of progesterone on breast tumor 
development, growth and metastasis.  While most steroid receptor-expressing tumors 
express the ER in addition to the nPR, there are reported cases of ER-/nPR+ tumors.  
Patients with ER-/nPR+ tumors have a poorer clinical outcome than patients with 
ER+/nPR+ tumors with a significantly higher incidence of tumor recurrence and a three 
times higher death rate (Keshgegian and Cnaan, 1996).  Though a role for progesterone in 
breast cancer is difficult to define (Lange, 2007), the results in the previous chapter are in 
agreement with those of recent studies showing that progestins act to promote 
immortalized breast cancer cell growth (Boonyaratanakornkit et al., 2007; Carnevale et 
al., 2007; McGowan et al., 2007; Migliaccio et al., 1998; Skildum et al., 2005) and inhibit 
cancer cell apoptosis (Moore et al., 2000; Moore et al., 2006; Ory et al., 2001; Vares et 
al., 2004).  These actions of progesterone often occur via nPR activity but progesterone 
has been shown to inhibit apoptosis in the absence of the nuclear progesterone receptor, 
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as demonstrated in Chapter 3, indicating that progesterone may be acting through an 
alternative progesterone receptor to maintain cancer cells.   
This study uses quantatitative reverse-transcription PCR to determine the levels of 
steroid receptor expression.  The likely responsiveness of tumors to steroids was 
originally determined via biochemical characterization of nuclear receptors in biopsied 
tissue.  Ligand binding using radiolabeled estrogen receptor agonists and progesterone 
receptor agonists was used to determine ER/nPR concentration where a minimal steroid 
binding level (mol steroid/mg protein) was established to determine steroid receptor 
positive or negative status (Geyer et al., 1985).  Recently, immunohistochemical 
detection of ER and nPR has replaced biochemical characterization to determine tumor 
steroid receptor status.  Breast tumors are known to express at least two forms of the ER 
(α and β) as well three forms of the nPR (the full length nPR-B and two truncated forms 
nPR-A and nPR-C).  In addition, several studies demonstrate the presence of novel 
steroid receptors in breast tumors including the estrogen binding GPR30 (Filardo et al., 
2007; Filardo and Thomas, 2005; Thomas et al., 2005) and the current study 
demonstrates mPRα, β and γ expression in breast tumors, all of which have been shown 
to bind progesterone in other expression systems and tissues (Karteris et al., 2006; 
Thomas et al., 2007; Zhu et al., 2003a).  Biochemical characterization of tumor steroid 
receptor status does not yield information on the identity of the receptor binding the 
steroid.  Immunohistological testing of breast biopsies is able to yield information on the 
receptor types expressed in the tumor and also the tissue localization of the receptors and 
is currently the favored method.  Yet it is often difficult to determine receptor 
concentration between samples and between receptors in immunohistological diagnostics 
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due to differences in antibody strength.  Thus, studies, including this one, have begun to 
use quantitative PCR to examine the identities and levels of steroid receptors expressed in 
tumors (De Bessa et al., 2006; Latil et al., 2001; Perou et al., 2000; Sorlie et al., 2001).  
Quantitative PCR has the advantages of being able to examine receptor expression in 
very small tissue or cell samples as well as yielding data on the levels of specific steroid 
receptors present relative to each other.  In addition, the development and 
characterization of primers directed against genes for quantitative PCR takes a relatively 
short period of time and yields a higher level of specificity in comparison to generation 
and characterization of antibodies directed against proteins.  The most problematic 
disadvantage of using PCR to examine gene expression is that it does not measure protein 
levels.  Additionally, biopsies contain variable amounts of receptors in neoplastic tissue 
compared to non proliferative tissue and while laser assisted micro-dissection now allows 
for the selection of a specific cell type for PCR analysis immunohistochemistry is often 
the method of choice in determining the pattern of receptor expression between different 
cell types in and around the breast tumor.     
In the present study mPRγ was upregulated in the majority of tumors in which any 
mPR isoform was upregulated but the upregulation of mPRα and mPRβ demonstrated 
patterns different from mPRγ and from each other.  mPRα and mPRβ were upregulated in 
45% and 40% of the tumors examined respectively.  Of the 60% of tumors in which 
either mPRα or mPRβ were upregulated only 23% showed upregulation of both isoforms.  
The differences in individual tumors between mPRα and mPRβ upregulation suggest that 
mPR isoform expression patterns may be important in breast cancer biology.  The 
patterns of steroid receptor isoform expression often differ between normal and 
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malignant breast and have been shown to affect the clinical response to treatment and 
prognosis.  Studies examining the expression patterns of ERα and ERβ show unrelated 
differential expression patterns of the two receptors in malignant breast tissue and suggest 
that ERβ is downregulated in malignant breast tissue (Shaw et al., 2002).  Other studies 
show that tumors which express high levels ERβ in addition to ERα respond more 
favorably to endocrine therapy (Hopp et al., 2004b; Lin et al., 2007) and suggest that the 
patterns of ERα and ERβ expression relative to each other may influence the expression 
of estrogen responsive cell proliferation genes (Shupnik, 2007).   The ratios of 
progesterone receptors have also been shown to influence response to treatment and 
prognosis.  The ratios of nPR-B and the truncated nPR-A are associated with the 
histological grade of the tumor (Ariga et al., 2001) and are suggested to influence the 
response to tamoxifen where patients with a higher ratio of nPR-A to nPR-B have lower 
disease-free survival rates than those with a low ratio (Hopp et al., 2004a). While there is 
currently no data on the expression patterns of the mPRs in relation to treatment response 
or prognosis, other studies suggest that the ratios of steroid receptor isoforms influence 
both of these factors and suggest that further study of mPR ratios in relation to treatment 
and prognosis is warranted.     
Cytokeratin19 (CK19) expression was measured in the current study and its 
upregulation in malignant breast tissue was found to be linearly correlated with mPRγ 
upregulation.  Regression analysis between CK19 and mPRγ malignant to normal ratios 
indicated that expression levels of the two are positively correlated.  CK19 is a 
commonly used breast epithelial cell marker.  It is most often used as a diagnostic tool to 
examine circulating epithelial cell levels of breast origination and indicates lymph node 
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metastasis (Iakovlev et al., 2008; Ji et al., 2006; Visser et al., 2008).  CK19 is normally 
heterogeneously expressed in breast tissue with expression in lumnal cells, although its 
expression appears to be upregulated and homogeneous in breast tumors (Su et al., 1996).  
CK19 also appears to be an important prognostic tool in tumors.  A lack of CK19 
expression in tumors was associated with high rates of relapse both at the tumor site and 
distantly as well as decreased survival rates (Parikh et al., 2008).  Although this study 
does not directly examine mPR upregulation in relation to prognosis, the positive 
correlation between CK19 expression and mPRγ may indicate a favorable prognosis for 
patients with mPR expressing tumors.   
There was no upregulation of any steroid receptor, including the mPRs, in three of 
the thirteen tumors examined in this study.  One of the three tumors is classified as a 
medullary carcinoma while the others are characterized as infiltrative ductal carcinoma.  
Medullary carcinomas are often characterized as having low CK19 expression, being 
mostly ER-/PR- and often Her-2/neu positive (Jensen et al., 1996; Larsimont et al., 1994; 
Xu et al., 2003).  The Her-2/neu gene encodes epidermal growth factor receptors and is 
upregulated in around 25% of breast cancers (Slamon et al., 1987; Slamon et al., 1989).  
Although much remains unknown concerning the interaction between steroid 
responsiveness and Her-2/neu over-expression in tumors, several studies suggest a link 
between the two.  Multiple studies suggest that Her-2/neu over-expression may be 
associated with tamoxifen resistance in both steroid responsive and unresponsive tumors 
(Konecny et al., 2003; Nicholson et al., 1990; Peiro et al., 2007; Wright et al., 1992).  
While Her-2/neu was not measured in this study, and no direct associations between the 
mPRs and Her-2/neu can be made, the lack of upregulation of any mPR isoform in the 
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absence of other steroid receptors suggests that the pattern of mPR expression in relation 
to Her-2/neu may mirror patterns seen between nuclear steroid receptors and Her-2/neu.  
 
Conclusions 
This study is the first to examine mPR expression in the human breast and clearly 
demonstrates that the mPRs are expressed in human breast tissue and that they are 
upregulated in nearly 80% of the tumors examined.  While mPR transcript levels may be 
low compared to other steroid receptors, their expression patterns suggest that they may 
play a role in breast cancer biology.  Of particular interest are the mPRα and mPRγ 
isoforms in that they positively correlate with nPR and CK19 upregulation in breast 
tumors respectively, both of which are associated with a positive prognosis.  The patterns 
of mPR isoform expression in relation to other mPRs, nuclear steroid receptor isoforms, 
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1 62 W Infiltrative Ductal Carcinoma II 
2 30 UNK Infiltrative Ductal Carcinoma II 
3 79 W Infiltrative Ductal Carcinoma III 
4 64 B Medullary Carcinoma III 
5 37 W Infiltrative Ductal Carcinoma II 
6 80 W Infiltrative Ductal Carcinoma III 
7 27 W Infiltrative Ductal Carcinoma III 
8 50 UNK Infiltrative Ductal Carcinoma  
9 60 UNK Infiltrative Ductal Carcinoma III 
10 51 UNK Infiltrative Ductal Carcinoma I 
11 47 UNK Pleomorphic Lobular Carcinoma III 
12 75 UNK Infiltrative Ductal Carcinoma  
13 37 UNK Infiltrative Ductal Carcinoma II 
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Table 4-3:  Gene regulation between paired normal and malignant samples.  (+) denotes 
a ratio of malignant to normal gene expression greater than 1.2.  (–) denotes a ratio of 



















1 - + + + + - + - 
2 + + - + - - + + 
3 + + - + + - + - 
4 + - - - - - - - 
5 + + + + + - + - 
6 + + - + + - + - 
7 + - - - - - - - 
8 + + + + + + + + 
9 - - + - + - - + 
10 + - - + - + - + 
11 + - - + - - - + 
12 + - + + - - + - 










































Figure 4-1:  Average gene to actin ratio in normal and malignant tissues.  Data represent 



















Figure 4-2: mPRγ linear correlation with nPR and CK19.  Data represent the ratio of 
malignant to normal gene expression for each biopsy pair.   A. Linear regression analysis 
indicates a positive slope of m = 14.42 ± 3.846.  The deviation from m=0 was significant 
with P<0.005 and r2= 0.5609. B.  Linear regression analysis indicates a positive slope of 
m = 0.1430 ± 0.02262.  The deviation from m=0 was significant with P<0.0001 and r2= 
0.784    

























Summary and Conclusions 
 
 The results from the present study support the hypotheses that the mechanism of 
mPR signaling and the biological function of the mPR in the somatic cells of female 
reproductive tissues are conserved across vertebrates and suggest that the mPRs may 
have significance in human disease.  In addition, the current study proposes a novel 
function for the mPR in female reproductive tissues.  Studies on the signaling of mPR in 
both the teleost ovarian follicle and immortalized human breast cancer cell lines 
demonstrate that progestin acts through the mPRs to activate inhibitory G proteins, 
decrease intracellular cAMP and activate ERK.  mPR activation of inhibitory G protein 
signaling pathways in both fish and humans indicates that the mechanism of mPR 
intracellular signaling appears to be conserved in female tissues across vertebrate classes.  
In addition, the mechanism of mPR signaling appears to be conserved in female 
reproductive tissues as mPR signaling through inhibitory G proteins has now been shown 
in the ovarian follicle and breast by the current study, and in the oocyte and myometrium 
by previous studies.   
The present study also suggests a novel function for the mPR in the somatic cells 
of female reproductive tissues.  Studies in both fish ovarian follicle cells and 
immortalized breast cancer cells demonstrate progestin inhibition of apoptosis in a 
manner consistent with mPR mediation.  Although progestin inhibition of apoptosis 
mediates two physiologically different results, mediation of spawning synchronization in 
the fish ovarian follicle and promoting the diseased, neoplastic nature of immortalized 
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breast cancer cells, the actions of progestin via mPR activation appears to be the same.  
While the complete intracellular signaling cascade leading from the mPR to inhibition of 
DNA fragmentation has not been elucidated and requires further study, it is plausible that 
activation of ERK and potentially Akt by the mPR are involved.   
The findings from this study also strongly suggest a significant role for the mPR 
in breast cancer biology.  In addition to mPR involvement in progesterone’s anti-
apoptotic effect in immortalized cells enabling diseased cells to continue to survive and 
grow in the absence of growth factor signals, the mPRs are upregulated in the malignant 
tissue from the majority of breast cancer patients examined.  Of the three predominant 
human mPR isoforms (mPRα, mPRβ and mPRγ) mPRγ, about which little is known, 
appears to be the most prevalent in breast tumors and may suggest a role for this isoform 
in cancer biology.  mPRγ upregulation correlated with nPR expression and CK19 
suggesting a role for the mPRs in steroid responsive tumors of epithelial origin.   
This series of studies show that mPR signaling and function are conserved in 
female tissues across vertebrate classes and suggest a novel function for the mPR.  While 
further investigations into the mechanism of mPR mediation of progestin’s protective 
affect and the role of the mPRs in breast tumors are needed, the current study is a 
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